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Alzheimer’s disease (AD) is the most common form of dementia with almost 50 million people 
affected and unfortunately, no cure or treatment to halt the disease progression is available. In 
the hereditary forms of AD, an overproduction of amyloid β (Aβ) and the Aβ plaque formation 
are the basis for the amyloid hypothesis of AD, while several additional factors seem to 
influence the likelihood to develop sporadic forms of AD. Inflammation, mitochondrial 
dysfunction, neurotransmitter alterations, defective autophagy processes, the ApoE4 gene 
variant, oxidative stress and lack of neurotrophic support, are other established alterations 
associated with sporadic forms of AD. 
The main aim of this thesis was to advance non-amyloidogenic drug discovery projects to 
improve the treatment options in AD. 
The first target for drug discovery research in this thesis was the 15-lipoxygenase-1 (15-LO-1) 
enzyme, which oxidizes polyunsaturated fatty acids and forms both reactive oxygen 
intermediates and pro- as well as anti-inflammatory metabolites. The 15-LO-1 activity has been 
found upregulated in the brain of AD patients. Inhibitors of 15-lipoxygenase have therefore 
been suggested as potential therapeutic substances for AD. In Study I, we developed a high-
throughput screening assay with the aim to identify 15-LO-1 inhibitors. An automated assay in 
384-well format using fluorescent analysis amenable for high-throughput screening was 
established. Potent 15-LO-1 inhibitors were identified, which may be a useful tool to evaluate 
the inflammatory component of AD. 
The second target for drug discovery approaches in this thesis was the altered neurotrophin 
signaling observed in AD. Basal forebrain cholinergic neuronal degeneration is one of the 
earliest signs of AD leading to cognitive impairment, described as the cholinergic hypothesis 
of AD. Associated with this impairment in the brains of patients with AD is the reduced nerve 
growth factor (NGF) signaling. The cognitive dysfunction seen in AD is also linked to the 
memory formation process in the hippocampus and the brain derived neurotrophic factor 
(BDNF) signaling. To modulate neurotrophin signaling, we investigated three NGF mutants in 
Study II and identified two small molecular compounds in Study III and IV that improve NGF 
and BDNF signaling. 
In Study II we showed that the hereditary sensory and autonomic neuropathy type V (HSAN 
V)-like mutant (NGF-R100E), displayed more potent activation of the neurotrophin receptor 
TrkA and could promote cell survival and neurite outgrowth to a higher degree than wild-type 
NGF itself in human fetal dorsal root ganglion (DRG) neurons. In Study III we identified a 
class of steroid derivatives which potently enhanced both the TrkA and the neurotrophin 
receptor TrkB signaling. Compound AC-25793, a soluble cardenolide was investigated further, 
which attenuated cognitive dysfunction and decreased depressive-like symptoms in vivo in 
mice. In Study IV we discovered a registered drug that enhanced NGF and BDNF signaling, 
increased long-term potentiation in rat hippocampal slices, increased acetylcholine levels after 
microdialysis in rats, improved cognitive functions and reduced depression-like symptoms in 
both mice and rats. The results using this compound, named ACD855 by us, suggest a 
compound with promising potential for treating cognitive deficiency and depression in AD. 
In summary, these findings have contributed to further knowledge in drug discovery projects 
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Neurodegeneration in the central nervous system (CNS) is part of the normal aging process but 
found accelerated and specified to certain brain areas in neurodegenerative disorders, with 
selective loss of neurons and specific loss of functions. Mutations in a broad variety of both 
related and unrelated genes are linked to hereditary forms of neurodegenerative diseases. 
Although a majority of the observed cases are sporadic, there are also many examples of 
familial neurodegenerative diseases. One hallmark of certain neurodegenerative diseases is the 
accumulation and deposition of misfolded proteins that cause toxic aggregates. In Alzheimer’s 
disease (AD) an accumulation and deposition of both amyloid β (Aβ) and hyperphosphorylated 
tau (p-tau) protein occur. Parkinson’s disease (PD) is recognized by misfolded alpha-synuclein, 
Creutzfeldt-Jakob disease (CJD) by infectious prion proteins, dementia with Lewy bodies 
(DLB) by misfolded inclusions identified with ubiquitin antibodies and in Huntington’s disease 
(HD) mutated and misfolded huntingtin protein form toxic aggregates. Despite the differences 
in symptomatology and underlying molecular pathways, several neurodegenerative diseases 
share common features, unfortunately also that they so far are incurable, with only partial 
symptomatic treatments available. 
 
1.2 ALZHEIMER’S DISEASE 
Alois Alzheimer examined 1901 a middle-aged woman with specific memory deficits and 
progressive loss of cognitive abilities, including poor spatial orientation and suspicion. 
Following her death five years later, an autopsy of the brain showed distinct morphological 
alterations, now known to be extracellular Aβ plaques and intracellular neurofibrillary p-tau 
tangles. This form of dementia was subsequently given the name Alzheimer’s disease 
(Alzheimer, 1907; Alzheimer et al., 1995). 
AD is the most common form of dementia with almost 50 million people affected worldwide 
(alzheimers.net), corresponding to about 50-75% of all dementia cases (Lane et al., 2018). 
Dementia, including AD, is a major cause of disabilities and the overall burden from AD is 
considerable, with encountered patients and family members, and immense social costs. With 
increasing life expectancy, the number of people with AD is expected to triple by 2050 (Lane 
et al., 2018). About 175,000 people in Sweden are today living with a dementia diagnosis, 
where 68% of people identified with dementia in 2018 were diagnosed with AD or mixed AD 
(SveDem, Yearly report, 2018). The financial burden for the Swedish society connected to 
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There is increasing evidence demonstrating that AD has a long preclinical phase (10-20 years) 
with neuronal loss and changes in biomarkers (Masters et al., 2015). Decreased cerebrospinal 
fluid (CSF) Aβ1-42/Aβ1-40 ratio is linked both to high Aβ deposition in the brain, with increased 
risk to develop AD, as well as with the clinical phase of AD. Levels of total tau and 
phosphorylated tau is increased in CSF and in the brain in AD. Both Aβ and tau can be 




Figure 1. Biomarkers and pathophysiology of AD. A proposed hypothetical model of biomarkers related to the 




The preclinical stage of AD eventually develops to mild cognitive impairment (MCI) which 
usually involves subtle decline in episodic memory, problems with independence, difficulties 
planning and completing a task, without considerably interfere with daily life activities, but 
where the decline is greater than in the expected cognitive weakening of normal aging 
(Winblad et al., 2004). A person with MCI has an increased risk of developing AD, but MCI 
can also reverse to a normal stage or advance to other dementias (Michaud et al., 2017). 
The clinical symptoms associated with AD are gradual loss of memory, further problems with 
planning and problem-solving, poor judgment, changes in personality, confusion, 
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aggressiveness, language and orientation problems, social withdrawal, depression, problems 
with daily activities, suspicion and illusions. The symptoms may vary from person to person, 
while the characteristic of dementia is the progressive decline over time. 
 
1.2.2 Diagnosis 
Diagnosing AD normally starts with an exclusion of other disorders. In Sweden the diagnostic 
work-up for dementia is recommended in the National guidelines published by the Swedish 
Board of Health and Welfare. When suspecting memory decline, a basal dementia work-up 
should be performed, including history from patient and caregiver, a Mini-mental state 
examination (MMSE), clock test, functional assessment and a computed tomography (CT) scan 
of the brain (Swedish Board of health and welfare. National guidelines on dementia care, 2010, 
revised, 2017). MMSE is a questionnaire that test memory, language, orientation, attention, 
ability to plan and visual abilities, but does not test the mood swings often related to AD 
(Folstein et al., 1975). The maximum score is 30 with an estimated decline in MMSE score of 
3-4 points per year in untreated and 2.5 points per year in AD patients treated with a 
cholinesterase inhibitor (Han et al., 2000; Lopez et al., 2002). Dementia has been staged based 
roughly on MMSE scores, i.e. suggested mild dementia with an MMSE score of  20, 
suggested moderate dementia with an MMSE score of 10-19 and suggested severe dementia 
with an MMSE score of <10. A draw back with the absolute number of MMSE score, is that it 
is affected by the person’s education level and the ability to master the language. A more 
extensive investigation is performed at memory clinics including a biomarker investigation of 
CSF after lumbar puncture, magnetic resonance imaging (MRI) and thorough cognitive testing. 
The average survival length after a clinical diagnosis of AD is 4-8 years in people over 65 years 
of age, but individuals may live up to 20 years after diagnosis (Alzheimer’s Association, 2016; 
Garcia-Ptacek et al., 2014). Bronchopneumonia has been found to be the most common cause 
of death in AD patients, followed by ischemic heart disease (Brunnström and Englund, 2009), 
while data on causes of death on individuals with dementia from the Swedish Dementia 
Registry (SveDem) showed that the most common  cause of death was ischemic heart disease 
(Garcia-Ptacek et al., 2016). 
 
1.2.3 Genetics and risk factors 
Age is the strongest risk factor for developing sporadic AD and old women are at special risk 
(Fratiglioni et al., 1997). At 65 years of age, about 1-3% of the population is presumed to have 
AD and after 65 years of age, the incidence of AD increases exponentially (Masters et al., 
2015). Less than 1% of AD cases are hereditary forms (Masters et al., 2015) and the majority 
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of the mutations causing AD are situated in the amyloid precursor protein (APP), or in the 
presenilin protein 1 or 2 (PSEN1 or PSEN2) genes. These mutations are autosomal dominant 
and cause early-onset AD (EOAD), also known as familial Alzheimer’s disease (FAD) 
(Lanoiselée et al., 2017). These mutations predominantly cause an overproduction of Aβ, 
especially increased production of Aβ1-42 (Masters et al., 2015).  Another genetic risk factor for 
AD is trisomy 21 (Down syndrome). Individuals with Down syndrome has a triplication of the 
APP gene, located on chromosome 21q21. The increased production of APP and Aβ in these 
individuals lead to an increased risk to develop EOAD (Hartley et al., 2015). FAD exhibits a 
penetrance that is close to 100%, with a relatively predictable age of onset from family to 
family, and is usually more aggressive than late onset AD (Mendez, 2017). 
The most common genetic risk factor for sporadic or late onset AD is the APOE ε4 gene variant 
of the apolipoprotein E (ApoE), a protein with three isoforms, APOE ε2, APOE ε3 and APOE 
ε4. The risk to develop AD is predicted to be three times higher for heterozygous APOE ε4 
carriers and 15 times higher for homozygous APOE ε4 carriers compared with the APOE ε3 
variant, which is the most common genetic variant, while APOE ε2 reduces the risk to develop 
AD (Van Cauwenberghe et al., 2016). The main function of the ApoE protein in the brain is to 
transport lipids and cholesterol to the neurons. The ApoE protein also binds to Aβ and 
facilitates Aβ clearance from the brain, a process where the ApoE4 protein is assumed to be 
less effective. 
There are at least 20 other genes linked to AD, for example the disintegrin and metallo-
proteinase domain-containing protein 10 (ADAM10), triggering receptor expressed on 
myeloid cells 2 (TREM2) and sortilin related receptor 1 (SORL1) (Hardy et al., 2014; Van 
Cauwenberghe et al., 2016). A number of lifestyle factors have also been identified to affect 
the risk of developing late onset AD. Positive influences from a balanced died, higher 
education, mental challenges, physical exercise and social activity have been shown. On the 
other hand increased risks for sporadic AD have been shown to be linked to stress, sleep 
disturbances, diabetes, cardiovascular diseases, high-fat or high-sugar diets, alcohol abuse, 
smoking and high blood pressure (Fratiglioni et al., 1993; Winblad et al., 2016).  
 
1.3 ALZHEIMER’S DISEASE PATHOLOGY 
Early events in the pathogenesis of AD are disturbed cholinergic function and synaptic 
dysfunction, both of which are highly correlated with cognitive dysfunction. As the disease 
progresses, neuroinflammation, neuronal death, and loss of synaptic connections with 
subsequent shrinkage of the brain occur (Winblad et al., 2016). The AD brain pathology is 
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characterized by atrophy, causing reduced brain volume, enlarged ventricles and hippocampal 
atrophy, with widespread neuronal death and with extracellular Aβ plaques and intracellular 
neurofibrillary tangles (Deture and Dickson, 2019). According to the amyloid hypothesis, 
accumulation and deposition of Aβ peptides is the driving pathology in AD (Selkoe and Hardy, 
2016).  
 
1.3.1 Amyloid β 
APP is widely distributed in the human body and is found abundant in the synapses of neurons. 
APP is sequentially cleaved first by α-secretase or β-secretase and then further cleaved by γ-
secretase, producing the P3 fragment after α-secretase cleavage or the Aβ peptide after β-
secretase cleavage. The γ-secretase is a protein with four main subunits, PSEN1, PSEN2, 
nicastrin and anterior pharynx defective-1 (Aph-1) (Sherrington et al., 1995). The α-secretase 
cleavage is called the non-amyloidogenic pathway, since the P3 fragment is not prone to 
aggregate, and is also the main route under normal conditions. The β-secretase pathway, the 
amyloidogenic pathway, results in increased production of Aβ peptides, and is believed to have 
a fundamental role in the AD pathogenesis (Zhou et al., 2011). The Aβ fragments may be of 
variable length, Aβ1-40 being the most common and Aβ1-42 being the most toxic and with the 
highest susceptibility to aggregate. (Selkoe, 2002).  
 
1.3.2 Tau 
P-tau protein that form intracellular neurofibrillary tangles are, beside Aβ plaques, a key 
pathological feature of AD. Tau phosphorylation is suggested to be secondary to Aβ 
accumulation in AD, since mutations related to FAD give rise to increased Aβ production and 
increased p-tau. Tau proteins are highly soluble microtubule-associated proteins that stabilize 
the microtubules in neurons and are vital for neuronal functions and axonal transport 
(Weingarten et al., 1975). The most common post-translational regulation of tau is via 
phosphorylation of its serine or threonine residues (Martin et al., 2011), regulated by kinases, 
an event that causes tau to detach from the microtubules. P-tau protein form insoluble 
intracellular neurofibrillary tangles in the form of paired helical filaments found in AD. The 
tau pathology observed in AD is probably a combination of loss of normal tau function and a 
gain of toxic effect of the neurofibrillary tangles (Ballatore et al., 2007; Iqbal et al., 2014).  
 
1.3.3 Neuronal degeneration and the basal forebrain cholinergic system 
The synapses are the terminals were neurons communicate with each other, the utmost delicate 
part of the neuronal system. Synapses constantly modulate and adapt to the signaling pattern 
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in the brain. Due to their high ability to adapt, synapses are also highly vulnerable to toxic or 
environmental changes. Synaptic dysfunction and synaptic protein changes are early markers 
of AD pathogenesis (Spires-Jones and Hyman, 2014). 
Synaptic loss and neuronal degeneration, especially in the basal forebrain cholinergic neurons 
(BFCN) and their projections to hippocampus and cerebral cortex, are linked to early signs of 
cognitive decline and AD. This is described as “The cholinergic hypothesis of AD” (Bartus et 
al., 1982). Memory, learning and other cognitive functions transmitted via cholinergic neurons 
are dependent on the neurotransmitter acetylcholine (ACh). The levels of ACh are decreased 
in AD which is linked to degeneration of cholinergic neurons, reduced synthesis of ACh by 
choline acetyltransferase (ChAT), and to decreased neurotrophic support from nerve growth 
factor (NGF) signaling (Rinne et al., 1988; Schliebs and Arendt, 2011). The 
acetylcholinesterase (AChE) is responsible for the break-down of ACh in the synaptic cleft, a 
mechanism that reduce prolonged or excessive firing of the post-synaptic neuron via the 
muscarinic and nicotinic ACh receptors. To compensate for the decreased support from ACh 
signaling in AD, acetylcholinesterase inhibitors (AChEI) were developed as treatments in mild 
to moderate AD and are hitherto the only drugs in addition to the N-metyl-D-aspartat (NMDA)-
receptor antagonist memantine (see below) for the symptomatic treatment of AD (Knight et al., 
2018). 
In behavioral studies, the drug scopolamine is used to block the muscarinic ACh receptors to 
mimic the cognitive dysfunction in AD (Bartus, 2000; Bymaster et al., 1993). Scopolamine 
blocks both postsynaptic muscarinic receptors (mainly M1 and M3) and presynaptic 
muscarinic receptors (mainly M2 and M4). Scopolamine binding to postsynaptic muscarinic 
receptors prevents ACh signaling, which impairs learning and memory. Scopolamine binding 
to presynaptic muscarinic receptors reduces the negative feed-back of ACh release, causing a 
continuous release of ACh from the presynaptic neuron and an increased ACh signaling via 
nicotinic receptors, leading to over-activation of the nicotinic receptor and additional reduced 
cognitive functions (Newman and Gold, 2016). 
Another neurotransmitter with essential cognitive functions is glutamate. In the memory 
formation process, presynaptic neuronal stimulation releases glutamate, which signals via the 
α-amino-3-hydroxi-5-metyl-4-isoxazol-propansyra (AMPA) receptor. The glutamate 
activation of AMPA receptors causes an inflow of Na+ ions into the post-synaptic cell, which 
recruits more AMPA receptors. The increased intracellular Na+ concentrations and the high 
glutamate signaling activate post-synaptic glutamate/NMDA signaling, leading to an inflow of 
Ca2+ into the post-synaptic cell. The inflow of Ca2+ propagates the firing in the post-synaptic 
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neuron and induce effectors for synaptic plasticity, learning and memory formation, for 
example brain-derived neurotrophic factor (BDNF).  
Glutamate signaling via synaptic NMDA receptors has been shown to promote synaptic 
plasticity and neuronal survival, while excessive glutamate signaling via extrasynaptic NMDA 
receptors has been shown to induce cell death (Olivares et al., 2012). In animal models, the 
drug MK-801 is used to block NMDA receptors causing a memory deficiency with reduced 
glutamate signaling and impaired long-term potentiation (LTP), mimicking the disturbed 
glutamate signaling found in AD (Foster and Fagg, 1987; Huettner and Bean, 1988). 
 
1.3.4 Inflammation 
Inflammation with chronic immune reactions is found in diseased areas of the AD brain and 
therefore neuroinflammation has evolved as a third central pathology in AD (Kinney et al., 
2018), where an upregulation of cytokines mediates the pro-inflammatory state in the brain, 
and the main inflammatory mediators are tumor necrosis factor α (TNFα), interleukin 1 β 
(IL-1β) and IL-6 (Su et al., 2016). Arachidonic acid, a polyunsaturated fatty acid, and its down-
stream metabolites are other key players involved in the immune response. Several well-known 
pathways and therapeutic targets are found within the arachidonic acid cascade, which have 
implications for the neuronal inflammatory process (AlFadly et al., 2019). Another significant 
contributing factor to the immune response is the microglial cells, which protect the brain from 
toxic proteins by clearing it from Aβ plaques, while in the diseased stage, large numbers of 
dysfunctional activated microglia are found within the lesions of AD (Heela and Heneka, 2017; 
Streit et al., 2020). The final stage of inflammation is the resolution stage, which involve 
specialized pro-resolving mediators (SPMs) for example lipoxins (LXs), which is found 




Lipoxygenases are iron-containing oxidizing enzymes in the lipid metabolism, using the 
catalytic ion to incorporate molecular oxygen into unsaturated fatty acid. One of the main 
substrates for lipoxygenases is arachidonic acid. The lipoxygenases are named after where on 
arachidonic acid they introduce the molecular oxygen (Funk et al., 2002). Arachidonic acid 
metabolizing enzymes like cyclooxygenase 1 (COX-1), cyclooxygenase 2 (COX-2) and 
5-lipoxygenase (5-LO) are well known for their production of pro-inflammatory metabolites, 
like the prostaglandins and the leukotrienes (Bergström and Samuelsson, 1962; Samuelsson, 
1983). There are three major lipoxygenases found in humans, 5-LO, 12-LO and 15-LO with 
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two different forms of 15-LO, named 15-LO-1 or 15-LO-2. The human 15-LO-1 enzyme 
corresponds to animal 12/15-LO, formerly called leukocyte type 12-LO. Mice, rats and pigs 
express the 12/15-LO (Takahashi et al., 1993). Rabbit reticulocytes express 15-LO-1, which is 
the only animal species known to express 15-LO-1. The human 15-LO-1 converts arachidonic 
acid to 15-hydroxy-(5,8,11,13)-eicosatetraenoic acid (15-HETE) and 12-hydroxy-(5,8,10,14)-
eicosatetraenoic acid (12-HETE) in a 9:1 ratio, while the animal 12/15-LO converts 
arachidonic acid mainly to 12-HETE (Kuhn et al., 2002). 15-LO-2 has little in common with 
15-LO-1, and is found in skin, cornea, lung and prostate (Brash et al., 1997). 
The human 15-LO-1 is selectively expressed in tissues like reticulocytes, eosinophils, airway 
epithelial cells and in the CNS (Joshi et al., 2015; Kühn and O’Donnell, 2006). The roles of 
15-lipoxygenase type 1 (15-LO-1) in humans are not as well investigated, as the role of 
12/15-LO in animals. Nevertheless, 15-LO-1 has been implicated in cytokine release from 
airway epithelial cells, asthma, cardiac inflammation, atherosclerosis and AD (Feltenmark et 
al., 2008; Praticò et al., 2004). Both pro- and anti-inflammatory actions are observed for 
15-LO-1 (Kühn and O’Donnell, 2006). The arachidonic acid metabolic pathway via 




Figure 2. The arachidonic acid metabolic pathway via 15-lipoxygenase-1, modified from Feltenmark et al. 
(Feltenmark et al., 2008). 15-LO-1 metabolize arachidonic acid by catalyzing the incorporation of molecular 
oxygen into arachidonic acid at carbon 15, producing 15-HPETE and by hydrolyzing 15-HPETE to EXA4. 
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The arachidonic acid derived cysteinyl containing 15-LO-1 metabolites, the eoxins (EX) were 
first discovered in human eosinophils (Feltenmark et al., 2008). The EXs have been shown to 
display pro-inflammatory actions in mast cells, eosinophils and lung epithelial cells 
(Feltenmark et al., 2008; Liu et al., 2009). The anti-inflammatory actions of 15-LO-1 is likely 
mediated via the arachidonic acid derived metabolites LXs (Sobrado et al., 2009). LXs are 
associated with suppression and resolution of inflammation. The chronic inflammation found 
in AD is linked to impaired resolution, where the pro-resolving mediator LXA4 is down-
regulated (Wang et al., 2015). 
Emerging evidence has demonstrated the involvement of 15-LO-1 in AD (Di Meco et al., 2017; 
Joshi et al., 2015). 15-LO-1 has been shown to be significantly upregulated in the brains of 
persons with AD or MCI (Praticò et al., 2004; Yao et al., 2005). 15-LO-1 has the ability to 
oxygenate both free fatty acids and fatty acids bound in membranes, which may lead to 
membrane damage and thereby contribute to inflammatory processes and neurodegeneration. 
The 15-LO-1 metabolites 12-HETE and 15-HETE are also important messenger molecules in 
the communication at the synapse, which may cause memory deficits with increased 15-LO-1 
expression (Piomelli et al., 1987). Oxidative stress occurs when there is an excess of free 
radicals, and increasing evidence suggest that oxidative stress is an early marker of the AD 
pathogenesis. The hydroperoxides, 15-hydroperoxy-(5,8,11,13)-eicosatetraenoic acid 
(15-HPETE) and 13-hydroperoxy-9,11-octadecadienoic acid (13-HPODE), formed when 
15-LO-1 oxidize arachidonic acid or linoleic acid, are potent mediators of oxidative stress and 
the subsequent neurodegeneration (Praticò et al., 2004). Furthermore, it has been shown in 
transgenic mice models of AD that overexpression of 12/15-LO augment the amyloid 
pathology, increase soluble tau levels and negatively affected memory functions, which could 
be ameliorated with a specific 12/15-LO inhibitor (Chu et al., 2015, 2012; Yang et al., 2010). 
Several attempts to target 15-LO-1 in the treatment of AD have been performed. AlFadley et 
al. performed a multi-target approach by targeting AChE, COX-2 and 15-LO-1 simultaneously, 
in line with the described deficient ACh signaling and neuroinflammation found in AD 
(AlFadly et al., 2019). A COX-2 and 15-LO-1 inhibitor could potentially reduce the 





NGF, BDNF, neurotrophin-3 (NT-3) and neurotrophin-4/5 (NT-4/5) belong to the 
neurotrophin family and signal via their respective high affinity tropomyosin related kinase 
(Trk) receptors and the low affinity p75 neurotrophin receptor (P75NTR, also known as p75) 
(Barde et al., 1982; Ernfors et al., 1990; Hallböök et al., 1991; Levi-Montalcini, 1952). For 




Figure 3. Neurotrophin signaling, where high affinity ligand binding is represented with a solid line and low 
affinity ligand binding with a dashed line. Pro-neurotrophins signal mainly via p75 causing apoptosis, while the 
mature neurotrophins signal via TrkA, TrkB and TrkC, according to figure, leading to cell survival events.  
 
 
Neurotrophin binding to Trk receptors can initiate down-stream signaling that may lead to cell 
survival, proliferation, differentiation, and synaptic plasticity, among other functions, while 
neurotrophin signaling via p75 mainly promote an apoptotic signaling pathway. 
The Trk receptors are cell surface receptors which are believed to dimerize upon neurotrophin 
binding, followed by an autophosphorylation of the receptor and then internalization of the 
neurotrophin-receptor complex (Franco et al., 2020), or shown by others to initially signal as a 
monomer and dimerize after internalization (Zahavi et al., 2018). The internalization of 
NGF/TrkA or BDNF/TrkB involves the formation of endosomes which mediate further 
signaling and retrograde transport of the complex, or may undergo recycling/degrading in the 
axon terminals (Marlin and Li, 2015; Yamashita and Kuruvilla, 2016). All the neurotrophins 
are expressed in a pro-form (immature neurotrophins), which are later cleaved to the mature 
proteins. Both the pro-forms and the mature forms of the neurotrophins are mainly found as 
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homodimers, where the molecular weight of the pro-form monomer is about 32 kDa and the 
mature monomer is about 13.5 kDa (Fahnestock et al., 2001). The high affinity receptor of the 
pro-forms of the neurotrophins is the p75 receptor (Kaplan and Miller, 2000). For a suggested 




Figure 4. Schematic representation of neurotrophin down-stream signaling pathways via p75 and Trk receptors, 
and subsequent intracellular events. Adapted with permission (Reichardt, 2006). 
 
 
NGF  is essential for nerve development prenatally and in the adult, BFCN maintain their 
reliance on NGF for survival and function (Hefti, 1986). In the healthy condition, the balance 
between pro-NGF and mature NGF proteins and their signaling via TrkA and p75 maintain the 
right level of support to the neurons for survival, differentiation, proliferation and apoptosis 
(Fahnestock and Shekari, 2019). The early and selective loss of BFCN in AD (Davies and 
Maloney, 1976) is linked to decreased support from NGF (Salehi et al., 2004; Seiler and 
Schwab, 1984). Several events related to NGF affect the cholinergic functionality during the 
AD pathogenesis such as altered NGF maturation,  skewed TrkA/p75 receptor ratio, inefficient 
axonal transport and signaling, Aβ induced modulation of NGF receptors and deficient ACh 
signaling (Mitra et al., 2019). The proNGF/NGF ratio is increased in AD patients (Fahnestock 
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et al., 2001), which leads to reduced retrograde transport of mature NGF from hippocampus 
and cortex to BFCN, and increased signaling via the p75 receptor causing increased apoptosis 
(Ito and Enomoto, 2016; Mufson et al., 2019). Lower levels of TrkA receptors in the basal 
forebrain and in cortex of AD patients further decrease the reduced NGF/TrkA signaling in the 
cholinergic neurons (Mufson et al., 1997). Furthermore, it has been shown in transgenic AD11 
mice, which express an anti-NGF antibody, that deprivation of mature NGF induces 
inflammation and evokes AD-like neurodegeneration with Aβ plaques and neurofibrillary 
tangles, suggested to be linked to the evoked proNGF/NGF imbalance (Capsoni et al., 2011a, 
2000). NGF is also linked to the Aβ pathology found in AD patients. NGF has been shown to 
directly reduce Aβ generation, and Aβ may prevent NGF maturation, which indicate how 
reduced NGF levels in AD patients might worsen the Aβ linked AD pathology (Bruno et al., 
2009; Mitra et al., 2019). The NGF-dependent vulnerability of BFCN degeneration in AD is 
suggested to augment the disease, which is proposed to be linked to the skewed proNGF/NGF 
ratio (Capsoni and Cattaneo, 2006; Cuello et al., 2019). 
 
High expression of BDNF and TrkB is mainly found in the human brain where it displays a 
significant impact on synapse plasticity and neurogenesis (Miranda et al., 2019). BDNF is 
defined as one of the most important factors for memory formation (Bekinschtein et al., 2014). 
Polymorphism in the proBDNF gene, the BDNF-Val66Met genotype, has been shown to cause 
lower levels of BDNF and is linked to significant increase in cognitive decline and hippocampal 
atrophy in both sporadic AD and FAD (Lee et al., 2013; Lim et al., 2018, 2016, 2013). 
Decreased levels of BDNF is also linked to depression, attention deficits, less stress tolerance, 
poorer weight control, insulin resistance and ADHD (Chan et al., 2019; Luo et al., 2020; Malhi 
and Mann, 2018; Motamedi et al., 2017; Notaras and van den Buuse, 2020), and BDNF levels 
are found increased after conventional anti-depressant treatment (Björkholm and Monteggia, 
2016; Notaras and van den Buuse, 2020). 
Both dementia and depression is common in the older population, and the comorbidity between 
the two disorders is extensive (Enache et al., 2016). The underlying reasons for the relationship 
between depression and neurodegenerative disorders, such as AD, is not fully understood, but 
there has been found similar neurodegenerative features in the brain of persons with dementia 
and depression (Bennett and Thomas, 2014), with strong correlations to inflammation and 
decreased levels of BDNF (Chi et al., 2014). 
Intensive exercise has been shown to increase plasma BDNF levels (Jeon and Ha, 2017; 
Marquez et al., 2015; Szuhany et al., 2015; Wang and Holsinger, 2018). It is not fully elucidated 
from where the exercise induced BDNF is derived. Both peripheral and central BDNF levels 
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have been shown to be increased after physical exercise in humans (Rasmussen et al., 2009), 
while animal studies have shown that exercised induced BDNF expression in the brain possibly 
is mediated via metabolic changes in the liver (Sleiman et al., 2016). 
The involvement of BDNF in hippocampal LTP is now well established (Lu et al., 2014; Woo 
and Lu, 2009). A long-lasting memory formation is dependent on BDNF expression 
(Navakkode and Korte, 2012), where lower serum levels of BDNF observed in AD patients 
(Ng et al., 2019) correlate with  induced hippocampal atrophy and cognitive decline (Lim et 
al., 2013). Besides the memory formation processes dependent on BDNF, the toxic effects of 
Aβ in the AD brain are more pronounced with lower expression of BDNF, as seen with the 
BDNF-Val66Met polymorphism (Lim et al., 2016) and the neurotoxicity seen with excessive 
glutamate signaling via NMDA receptors is reduced if BDNF is present (Lau et al., 2015). 
 
When NGF binds to TrkA or when BDNF binds to TrkB, a down-stream signaling cascade that 
can activate ERK1/2 (extracellular signal-regulated protein kinases 1 and 2), also known as 
mitogen-activated protein kinases (p42/p44 MAPK), which is part of the Ras-Raf-MEK-ERK 
(MAPK/ERK) pathway, is initiated. The ERK1/2 kinases are involved in the signal 
transduction and are co-transported with internalized NGF/TrkA or with BDNF/TrkB during 
retrograde transport (Delcroix et al., 2004). The ERK1/2 signaling pathway is involved in cell 
survival, differentiation and proliferation, but also apoptosis (Wortzel and Seger, 2011). 
 
1.6 TREATMENT OF ALZHEIMER’S DISEASE 
1.6.1 Current treatment 
Although it has passed over 100 years since AD was first described, there is still no curative 
treatment. Researchers, patients and caregivers have a strong desire for a disease-modifying 
AD treatment, which we are still waiting for. The first treatments available for AD, the AChEIs, 
were developed in the 1990s, and are symptomatic. Interestingly, despite 30 years of intense 
research, still the only available medications for AD besides memantine are the AChEIs. The 
first in line cognitive therapy in mild-to-moderate AD is an AChEI, which reversely inhibits 
the AChE. The AChEIs on the market are donepezil, galantamine and rivastigmine, which are 
able to slightly delay further cognitive decline (Birks and Grimley Evans, 2015; Hager et al., 
2014; Lee et al., 2015). In Sweden the national guidelines state that when AD is diagnosed, 
treatment with an AChEI is recommended (National Guidelines for the Care of Cases of 




Interestingly, the AChEIs have been shown to have effects on other symptoms than cognition, 
for example they have been found to reduce behavioral and psychological symptoms in 
dementia (Freund-Levi et al., 2014; Tan et al., 2020). Furthermore, the AChEIs have been 
associated with reduced mortality and a 35% reduced risk of death in myocardial infarction 
(Nordström et al., 2013) or stroke (Tan et al., 2018). 
A registered drug for treatment of moderate to severe AD is the glutamate receptor inhibitor 
memantine. Increased amount of glutamate causes an excessive glutamate signaling via the 
NMDA receptor, which leads to high intracellular calcium levels and cell death. Memantine is 
a partial antagonist of the glutamate receptor NMDA and is used to normalize the glutamatergic 
signaling, stop the prolonged influx of Ca2+ ions, and to prevent the glutamatergic neurotoxicity 
(Olivares et al., 2012), but the effects of memantine in AD are considered small (McShane et 
al., 2019). 
A meta-analysis from December 2018 found that donepezil or galantamine may show best 
effects on cognition in mild to moderate AD, while a combination of donepezil and memantine 
would be recommended for moderate to severe AD (Dou et al., 2018). 
Medications to AD patients might also involve treatments for behavioral changes, psychiatric 
problems, sleep disturbances and depression.  
 
1.6.2 The preclinical drug discovery process 
When discovered that the effect of extracts from plants, such as morphine from opium poppy, 
digitalis from foxglove and salicin (ancestor to acetylsalicylic acid) from willow bark, were 
derived from specific chemical substances, advanced pharmacology, chemical synthesis and 
drug discovery was established (Jones, 2011). Generally, small molecule drugs are chemically 
synthesized molecules that are designed to interact with a specific target protein. Small 
molecule compounds and biopharmaceuticals are today the two main research areas within 
drug discovery. The biopharmaceutical products include vaccines, blood, tissues, gene 
therapies, antibodies and living cells. 
Drug discovery is a long, complex and expensive process, involving both preclinical and 
clinical stages. The preclinical drug discovery process involves several phases including, target 
identification, assay development, hit identification (screening), lead identification and 
optimization, selection of a candidate drug (CD), safety pharmacology and toxicology as well 
as pharmaceutical development. Identification of a target protein is often the starting point 
when working with either small molecules or antibodies. The target or the receptor of interest 
is examined, a primary assay to study the effect of potential small molecules is developed and 
high-throughput screening of compound libraries are performed. Validated hits from the screen 
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are the starting points for chemical synthesis to optimize compounds. Structure-activity-
relationship (SAR) analyses are performed to compare the chemical structure and the biological 
activity of the compounds. Patentability of the compounds is usually addressed early in the 
drug discovery process. Secondary and selectivity assays are developed, to further profile the 
chemical compounds. Secondary assays are used to confirm on-target effects and selectivity 
assays are established to avoid side effects. As more potent and selective compounds within 
one chemical class are identified, one or a few lead compounds are identified. A lead compound 
is a compound with sufficient potency and selectivity on the target of interest and with a 
chemical structure that makes it amenable for optimization into a CD. Thereafter, one or more 
lead-classes are optimized and further evaluated regarding permeability, bioavailability, 
toxicity, metabolism, and in vivo effects. The development finally reaches a point where an 
optimized compound fulfills all or most of the requirements, whereby a CD is selected. The 
compound is then ready for safety and toxicology studies in animals before pharmaceutical 
development and clinical trials can be initiated. 
 
1.6.3 Future treatment 
Much effort has been directed to amyloid treatment, but so far, no Aβ reducing drug has reached 
the market. The clinical trials with anti-amyloid antibodies are struggling with limited effects 
on improvement of cognition within a defined population, but also with proof-of-concept, i.e. 
will a reduction of Aβ in the brain cure or halt the progressive neurodegenerative decline in 
AD and if so, at which state of the disease must treatment start to have a disease modifying 
effect (Tolar et al., 2019). Two anti-amyloid antibodies are at present of particular interest, 
aducanumab and BAN2401 (Panza et al., 2019). Aducanumab has shown a reduction of Aβ 
plaques but little clinical effects and with a high frequency of amyloid-related imaging 
abnormalities (ARIAs). The cerebral edema related ARIAs were found in one third of patients 
receiving the 10 mg/kg dose compared with 10% in the placebo group. Two ongoing phase III 
trials with aducanumab was discontinued in March 2019 following a futility analysis, but after 
reanalyzing the data Biogen announced in October 2019 that they will submit aducanumab for 
an FDA (the U.S. Food and Drug Administration) marketing approval for the treatment of early 
AD (Schneider, 2020). However, recently the negative first results of two anti-amyloid drug 
trials (solanezumab or gantenerumab) in persons with FAD, with known mutations in the APP-
gene, were reported (Washington University Press release (Feb 10, 2020), https://medicine. 
wustl.edu/news/alzheimers-diantu-trial-initial-results/), again dampening the enthusiasm for 
anti-amyloid therapies considerably. 
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The list of potential AD treatments is long and may involve several different target proteins 
and/or mechanisms. Suggested targets include Aβ clearance (Xin et al., 2018), Aβ anti-
aggregation (Kocis et al., 2017), p-tau immunotherapies (Congdon and Sigurdsson, 2018), 
γ-secretase modulators (Aguayo-Ortiz and Dominguez, 2018), counteract the loss of tau 
stabilization of microtubules (Lee et al., 2011), kinase inhibitors to prevent 
hyperphosphorylation of tau (Annadurai et al., 2017), regulators of oxidative stress (Jiang et 
al., 2016), anti-inflammatory agents (Ozben and Ozben, 2019), and modulators of 
neurotransmitter (Kandimalla and Reddy, 2017) and neurotrophin signaling (Mitra et al., 2019; 
Nordvall and Forsell, 2014). While β-secretase inhibitors may no longer be a preferred 
therapeutic target due to target related adverse events. Another approach for fighting AD is 
life-style changes. Various prevention studies have shown positive signs on improved 
cognition in persons at risk at developing AD or dementia, among them, professor Kivipelto 
and co-workers have shown positive effects on cognitive in the Finnish geriatric intervention 
study to prevent cognitive impairment and disability (FINGER) (Kivipelto et al., 2018). 
 
Several targets within the areas of inflammation, cholinergic signaling and neurotrophins could 
be amenable for pharmacological intervention and hence, potentially be of importance in future 
treatment of AD.  
In this thesis, we focused on targeting non-amyloid pathways in AD as exemplified by 
developing assays to identify 15-LO-1 inhibitors to reduce oxidative stress and inflammation 
and by the identification of small molecular compounds that can enhance neurotrophin 
signaling and improve cognitive functions. 
Systemic treatment with the NGF protein is associated with problems to reach the brain since 
BBB penetrance is very low and therapeutic doses of NGF to treat cognitive dysfunctions has 
been shown to cause low back pain (Eriksdotter Jonhagen, 1998). Trials with encapsulated cells 
delivering NGF directly to the basal forebrain of AD patients (Eriksdotter-Jönhagen et al., 
2012; Eyjolfsdottir et al., 2016; Mitra et al., 2019) and treatment with gene therapy in AD 
patients (Rafii et al., 2018; Tuszynski et al., 2005) have both shown indications of cognitive 
improvement, but the invasiveness of these therapeutics are a clear drawback. When 
intervening with the NGF/TrkA signaling pathway to promote survival of neurons, there is a 
risk to enhance pain signaling. Minde and co-workers identified a single point mutation in the 
NGF gene (NGF) linked to the hereditary sensory and autonomic neuropathy type V (HSAN 
V) in a family in northern Sweden (Einarsdottir et al., 2004; Minde et al., 2004). HSAN V is a 
rare disease with a loss of pain, heat and cold sensation, where homozygote cases are more 
severely affected than heterozygotes. Cognition is not affected in the HSAN V patients or in 
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heterozygous NGFR100W/wt mice (Testa et al., 2019b), and the mutant NGF protein found in this 
disease is therefore interesting from a drug discovery point-of-view.  
Small molecular treatments of both inflammation and neurotrophic signaling can be designed 
to cross the BBB to have effects on target cells. Inhibitors of 15-LO-1 may have the advantages 
to reduce inflammation without side-effects related to prostaglandin synthesis. 15-LO-1 
inhibitors derived from our initiative, for example BLX3887 and BLX769, have been used to 
further study the 15-LO-1 activity and inflammatory responses (Archambault et al., 2018). 
Enhancers of NGF and BDNF signaling can be optimized to mainly strengthen TrkA and TrkB 
signaling in the presence of NGF or BDNF respectively, i.e. positive modulators rather than 
pure agonists. This would reduce the risk for peripheral signaling via NGF/TrkA which cause 
pain, since peripheral NGF levels normally are elevated mainly during inflammation 
(McMahon, 1996; Skaper, 2017). Small molecule modulators of neurotrophin receptors have 
been evaluated for neuroprotection, improved cognition, neurite outgrowth, cell survival and 
differentiation, pain reduction, healing of dry eye targeting stroke, AD, PD, traumatic brain 
injury, peripheral neuropathic pain, Rett syndrome, HD, epilepsy etc. (Mitra et al., 2019). The 
antidepressant amitriptyline has been shown to activate TrkA/TrkB and down-stream signaling 
events (Jang et al., 2009), but both we and others had problem reproducing these results 
(Boltaev et al., 2017; Todd et al., 2014). A small NGF mimetic molecule, LM11A-31-BHS,  
targeting the p75 receptor for the treatment of mild to moderate AD is currently in a phase IIa 
clinical trial, where the primary outcome is safety and secondary outcomes include Aβ, tau, 
AChE activity and cognitive functions, with planed completion of the study in September 2020 










The overall aim of this thesis was to develop assays and identify small-molecule substances to 
advance drug discovery projects within non-amyloid pathways in Alzheimer’s disease. 
 
Study I 
The aim of this study was to develop a fluorescence-based assay, perform a high-throughput 
screen of a chemical library, with concomitant lead optimization, to identify small molecules 
inhibiting the 15-LO-1 protein. 
 
Study II 
This study aimed to elucidate the role of three nerve growth factor mutants and evaluate their 
ability to modify NGF/TrkA signaling. 
 
Study III 
This study aimed to screen a compound library, validate hits and to identify a potential enhancer 
of NGF and BDNF signaling with the ability to attenuate cognitive dysfunction. 
 
Study IV 
The aim of this study was to evaluate ACD855, as an enhancer of NGF and BDNF signaling 
for the treatment of Alzheimer’s disease. 
3 METHODOLOGY 
This is a summary of the methods used in this thesis. A more detailed description of the 
methodological procedures can be found in the materials and methods section of each paper. 
 
3.1 ETHICAL CONSIDERATIONS 
All animal experiments were carried out in accordance with the current European Law 
(Directive 2010/63/EU), where all efforts were made to minimize animal suffering and to 
reduce the number of animals used. Experimental procedures were approved by the regional 
ethical board in Stockholm, the guidelines of Karolinska Institutet and the Swedish Animal 
Welfare Agency. Ethical permission for the use of mice and rats in animal experiments in Study 
III and IV were obtained by the Stockholm Regional Committees. Human fetal dorsal root 
ganglion (DRG) tissues were collected with informed written consent after elective routine 
abortions (7 to 9 weeks post conception) at Karolinska University Hospital Huddinge. All 
studies on human material followed the declaration of Helsinki and the guidelines of 
Karolinska Institutet. The permission to use fetal tissue for Study II and III was approved by 




When developing drugs, the basis for the drug discovery is to define relevant assays that can 
be used as a model for the question of interest. Every model of a disease has its own advantages 
and disadvantages that must be considered when analyzing and interpreting data. Enzyme 
assays can provide the project with on-target effects, although with major limitations in the 
biological relevance. Overexpressing cells are biased in certain protein levels, whilst providing 
a model with detectable quantities of analyte in a physiological context. Primary cells represent 
an isolated model closer to the natural system, especially when derived from a human source. 
Experiments with rodents in vivo can provide drug discovery projects the reality of the living 
organism, although in a foreign species. 
 
3.2.1 Enzyme preparation 
In Study I, human eosinophils were isolated from whole blood as described before (Feltenmark 




Venous blood was collected from healthy volunteers or from patients with hyper-eosinophilia, 
but without hematological malignancies. Whole blood was centrifuged and applied to dextran 
separation. The white blood cell fraction was suspended in lysis buffer to remove 
contaminating red blood cells. Next, a gradient centrifugation using Lymphoprep was 
performed to abstract the polymorphonuclear cell fraction. Eosinophils were then isolated by 
negative selection using CD16 antibodies utilizing magnetic cell sorting. Purity was > 95%, 
tested with May-Grünwald-Giemsa solution. 
Total RNA was isolated from eosinophils and human 15-LO-1 cDNA was amplified by PCR. 
The 15-LO-1 cDNA was cloned into the pFastBac1 vector. Bacmid DNA was derived and Sf9 
insect cells were transfected. Viral particles were collected and amplified. The stock of viruses 
was used to infect Sf9 cells. 15-LO-1 was purified from the 20,000 g supernatant of 
homogenized Sf9 cells, fractions were pooled and stored at −80°C until use. The 15-LO-1 
enzyme was 90-95% pure as judged by Coomassie blue staining. 
 
3.2.2 Cell lines 
Immortalized cell lines are of great value both in basic research and in drug discovery. The use 
of immortalized cell lines does not require an ethical permit. There are many benefits with 
immortalized cell lines, which usually proliferate at a high rate, survive for many passages and 
are often easy to culture. Cell lines can grow both as adherent cells and or in a suspension, 
depending on the origin of the cell type. Drawbacks with cell lines are associated with cell 
types that are far from the origin of the disease, cells cultured without the three-dimensional 
network in a normal extracellular matrix or contamination of other cell lines (Kaur and Dufour, 
2012). 
In Study I we used the human Hodgkin lymphoma cell line (L1236) which expresses abundant 
levels of 15-LO-1 (Claesson et al., 2008). The L1236 cells were used to develop cell assays 
amenable for studying the inhibition of the human 15-LO-1 enzyme by small molecules in a 
screening mode. The L1236 cell line was cultured as suspension cells. 
In Study II we used rat adrenal gland pheochromocytoma (PC12) cells to study the effects of 
wild-type NGF and NGF mutants on cell survival and cell differentiation, and the 
phosphorylation potential of ERK1/2. PC12 cells are dependent on NGF for differentiation and 
are widely used to study neuronal changes in an immortalized cellular system (Greene and 
Tischler, 1976). PC12 cells are suspension cells that can be cultured as adherent cells using 
collagen IV coated flasks or plates. In this thesis we used adherent PC12 to study cell survival 
and neurite outgrowth. 
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Human bone osteosarcoma U2OS-TrkA/p75-SHC1 cells and U2OS-TrkB/p75-SHC1 cells, 
PathHunter® U2OS functional assays from DiscoverX, were used for screening and validation 
of small molecular compounds that can activate or enhance the neurotrophin signaling 
(NGF/TrkA and BDNF/TrkB). The U2OS-TrkA/p75-SHC1 and U2OS-TrkA-PLC1 cell 
assays were also used in Study II to compare the activation potential of TrkA between wild-
type NGF and NGF mutants. The U2OS cells are strongly adherent cells. 
 
3.2.3 Primary cell cultures 
A primary cell culture will often proliferate less than an immortalized cell line, as primary cells 
commonly are of a non-tumorous origin. When preparing primary cell cultures from animal or 
human tissues, an ethical approval is required, and the use of these cells should always be 
evaluated in the light of biological and ethical relevance. Optimal growth conditions to 
maintain the feature of the primary cell is often critical. 
In Study III we isolated primary cortical neurons (PCN) from mouse embryos on gestational 
day 17. PCN were used to study BDNF/TrkB mediated phosphorylation of ERK1/2 by the 
cardenolide AC-25793. 
To study activation of TrkA we isolated human fetal DRG neurons, which are dependent on 
NGF for survival and differentiation. In Study II we evaluated the capacity of NGF mutants to 
promote cell survival, differentiation, and phosphorylation of ERK1/2, compared with wild-
type NGF using DRG neurons. In Study III DRG neurons were used to evaluate the potency of 





Table 1. Cells used in experiments performed in Study I-IV. 
 
  
Study I Study II Study III Study IV
L1236 cells X
Cell PC12 cells X
U2OS-TrkA/p75-SHC1 cells X X X
lines U2OS-TrkA-PLC1 cells X
U2OS-TrkB/p75-SHC1 cells X X
Primary Mouse primary cortical neurons X









Figure 5. C57BL/6J laboratory mouse. 
 
 
In Study III and IV we used the C57 black 6 inbred mouse strain, originally from The Jackson 
Laboratory (C57BL/6J), to study in vivo effects of compounds that displayed potent 
neurotrophin enhancing effects in vitro. The C57BL/6J mice are the most widely used inbred 
laboratory mouse strain and they are well suited for behavioral testing performed with 
automated recording since their black coat creates a high contrast against the light background 
in most arenas. We used only male mice to reduce the influence by hormone cycles and the 
common barbering actions by the dominant female mouse, which could negatively influence 
the behavioral tests. C57BL/6 mice are known to be slightly more aggressive than other inbred 
laboratory mice, such as the Bagg albino inbred mouse strain (BALB/c) or the albino outbred 
mouse strain originally from Naval Medical Research Institute (NMRI) mice, but they are 
found attentive and respond well to behavioral testing. 
 
3.2.5 Rats 
In Study IV we used Sprague Dawley rats for LTP experiments and for microdialysis 
experiments, and Flinders Sensitive Line (FSL) rats in the forced swim test (FST). The FSL 
rats were first developed at Flinders University of South Australia through selective breeding 
techniques to be sensitive to the cholinesterase inhibitor diisopropyl fluorophosphate (DFP) 
(Overstreet and Russell, 1982). FSL rats have shown to be an animal model of depression, with 
high sensitivity towards behavioral treatment and changes in their cholinergic and serotonergic  
responses, thus responding well to cholinergic muscarinic antagonists such as scopolamine,  to 
AChEIs such as physostigmine and donepezil and to antidepressants (Blaveri et al., 2010; 








Here follows a description of the main analyses and assays used in this thesis. 
 
3.3.1 15-Lipoxygenase-1 assays 
The arachidonic acid metabolites have implication in many disorders, such as inflammation, 
fever, pain, coagulation, asthma as well as AD. 15-LO-1 inhibitors could be used to evaluate 
the inflammatory response generated by metabolites formed via the 15-LO-1 pathway in 
diseases such as AD. Since the human 15-LO-1 enzyme and the animal ortholog, the 12/15-
LO enzyme, differ in the generated products, assay development focused on the human variant. 
One of the substrates of the 15-LO-1 with high Vmax is linoleic acid. Linoleic acid was used 
in the high-throughput screening (HTS) to obtain a robust readout and to improve the assay 
parameters, although focus for 15-LO-1 inhibitory treatment is the arachidonic acid 
metabolites. 
 
3.3.1.1 15-LO-1 enzyme assay 
An aliquot of 15-LO-1 enzyme was thawed and diluted in phosphate-buffered saline (PBS) to 
reach a final concentration of 2.8 μg/ml. 15-LO-1 enzyme dissolved in PBS was mixed with 
compound dissolved in dimethyl sulfoxide (DMSO) or DMSO as a vehicle control in assay 
plates and pre-incubated for 5 minutes, with a final screening compound concentration of 10 
µM. Linoleic acid was added with a final concentration of 200 µM, and the mixture was 
incubated for another 10 minutes. The reaction was stopped with the addition of 2 volumes of 
methanol and 0.125 mM diphenyl-1-pyrenylphosphine (DPPP). Fluorescence was measured at 
380 nm. 
 
Study I Study II Study III Study IV
Hippocampal ERK1/2 analysis X X
Passive avoidance X X
Morris water maze X
Forced swim test X X
LTP analysis X
Microdialysis X






3.3.1.2 15-LO-1 cell assay 
L1236 cells were maintained in complete RPMI (Roswell Park Memorial Institute) 1640 cell 
culture media. Cells were washed and diluted in PBS before seeded in assay plates. Test 
compound dissolved in DMSO or DMSO vehicle was added to each well and the assay plate 
was incubated at room temperature for 10 minutes. Linoleic acid was added, and the mixture 
was incubated for another 30 minutes. The reaction was stopped with the addition of methanol 
for high-performance liquid chromatography (HPLC) analysis or with 0.125 mM DPPP in a 
methanol/DMSO (1:1) mixture for fluorescence analysis. 
 
3.3.1.3 HPLC analysis 
Before reverse-phase HPLC (RP-HPLC) analysis, assay plates were stored at −20°C for at least 
60 min, followed by centrifugation, to remove precipitated proteins. The supernatant was 
injected to a C18 column coupled to a HPLC system. Quantification of 13-hydroxy-9,11-
octadecadienoic acid (13-HODE) was performed by measuring absorbance at 235 nm. 
Qualitative analysis was performed by comparing retention time and occasionally the UV 
spectra of samples with 13-HODE standard. 
 
3.3.1.4 Fluorescent analysis 
To quantify the levels of product formation in the enzyme or the cell assay solution, we 
developed a fluorescent assay that was suitable for the reactions when the 15-LO-1 enzyme 
catalyzes the addition of  molecular oxygen into arachidonic acid or linoleic acid to form the 





Figure 6. The oxygenation of linoleic acid and arachidonic acid by 15-LO-1 and the formation of the 




DPPP is a non-fluorescent compound that reacts with hydroperoxides leading to fluorescent 
DPPP-oxide which emit fluorescence at 380 nm. The intensity of the fluorescent light from the 
DPPP-oxide revealed to be proportional to the amount of 13-HODE formed in the assay, as 
shown in figure 7. Fluorescence was measured using a fluorescence plate reader, 15-120 





Figure 7. Reaction between the lipid hydroperoxide 13-HPODE and DPPP leading to a fluorescent DPPP-oxide. 
 
 
3.3.2 Neurotrophin assays 
To test the hypothesis that small molecules that enhance neurotrophin signaling can rescue 
degenerating neurons and improve cognitive functions in AD, the following in vitro and in vivo 
assays were evaluated. 
 
3.3.2.1 PathHunter® chemiluminescence cell assay 
The primary assay, used to identify and validate small molecules that modulate neurotrophin 
signaling in this thesis, was a PathHunter® chemiluminescence cell assay from Eurofins 
DiscoverX Corporation. These commercially available enginered cell assays have been 
validated before (Forsell et al., 2013) and for studies in thesis we used U2OS-TrkA/p75-SHC1, 
U2OS-TrkA-PLC1, and U2OS-TrkB/p75-SHC1 PathHunter® cell assays.  
The U2OS-TrkA/p75-SHC1 cell assay principle is briefly described here and a simplified 
schematic picture is shown in figure 8. U2OS cells are stably transfected with the human TrkA 
receptor, which is recombinantly expressed with a small fragment of the β-galactosidase 
enzyme fused to TrkA at the intracellular C-terminus. The SHC1 protein is co-expressed in the 
U2OS cells with a larger fragment of the β-galactosidase enzyme. When the recombinant 
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U2OS-TrkA-SHC1 cells are treated with NGF, a dimerization and an autophosphorylation of 
the TrkA receptor occur. The phosphorylated TrkA receptor attracts various intracellular 
signaling proteins and the SHC1 protein binds the TrkA receptor at the phosphorylation site 
tyrosine 490 (Y490). The binding of SHC1 brings the two parts of the β-galactosidase enzyme 
in close proximity to each other, thereby leading to complementation which combines the two 
parts of β-galactosidase, generating an active β-galactosidase enzyme. After 3 hours of 
incubation at room temperature, a substrate is added to the assay and the active β-galactosidase 
enzyme converts the nonluminescent substrate to a lumiescent product. The luminescent signal 





Figure 8. The enzyme fragment complementation (EFC) assay technology using β-galactosidase from Eurofins 
DiscoverX Corporation. This figure describes the PathHunter® functional assay with U2OS-TrkA/p75-SHC1 
cells. Modified from Eurofins DiscoverX Corporation assay principle. 
 
 
3.3.2.2 Phospho-TrkA and phospho-ERK1/2 ELISA 
An enzyme-linked immunosorbent assay (ELISA) is a sensitive and specific method to detect 
proteins. The work effort is normally lower with ELISA than with for example western blot, 
thus the number of analyzes can be increased. To quantify the levels of phosphorylated TrkA 
or ERK1/2 in cell suspension, we used the human phospho‐TrkA DuoSet IC ELISA and 
phospho‐ERK1 (T202/Y204)/ERK2 (T185/Y187) DuoSet IC ELISA, both from R&D 
Systems, according to the manufacturer’s instructions. 
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3.3.2.3 Western blot analysis 
Western blot is an immune-based method to detect proteins by size and it is a sensitive and a 
specific method to detect and quantify proteins. In Study II, III and IV, western blot analysis 
was used to quantify and compare protein levels in cultured cells or mouse brain tissue.  
Briefly, the cells were lysed, or the mouse hippocampal tissue was sonicated, in standard lysis 
buffer complemented with protease and phosphatase inhibitors. Samples were mixed with 4X 
loading buffer, heated to 95°C for 5 minutes and loaded on Novex Bis-Tris 4-12% gels for 
protein separation. A dry gel transfer to polyvinylidene difluoride (PVDF) membrane was 
performed using an iBlot instrument. Membranes were blocked in a Tris-buffered saline (TBS) 
solution supplemented with 0.1% Tween and 5% nonfat dry milk or bovine serum albumin 
(BSA). Primary and secondary anti-bodies were diluted in a TBS-Tween solution 
supplemented with 5% BSA. Primary antibody phospho‐p44/42 MAPK (ERK1/2) 
(Thr202/Tyr204) rabbit monoclonal IgG1 antibody was from Cell Signaling. Secondary 
antibody was a horseradish peroxidase-coupled anti-rabbit antibody. Quantification was 
performed using Image Studio Lite. 
 
3.3.2.4  Immunocytochemistry analysis 
The immunocytochemistry analysis was utilized to examine NGF dependent proliferation and 
differentiation, and to study TrkA down-stream signaling. Compared to other immunoassays, 
immunocytochemistry assays allow for studies of protein expression at a cellular or subcellular 
level. This study tested the hypothesis that mutant NGF might affect cell survival, neurite 
outgrowth and activation of ERK1/2 differently, or that small molecules enhancing the 
NGF/TrkA signaling could potentiate neurite outgrowth in combination with NGF. Beta-
tubulin III antibody detects a specific tubulin found only in neurons (and testis cells), and make 
it possible to study neurite length, neurite branching, neurite width and other parameters linked 
to individual neurons. Secondary antibodies conjugated with Alexa Fluor dyes were used to 
visualize detected proteins and automated fluorescence imaging (Thermo Scientific Cellomics 
Array Scan VTI HCS Reader) was used to quantify the fluorescent signal. Automated 
examination of captured images was performed using a high-content imaging analysis software 
(Cellomics). 
Human fetal DRG tissue was collected and dissections were performed under sterile conditions, 
tissue collected in DMEM medium and disassociation of ganglia to isolate single cells started 
within one hour. Ganglion tissue was dissociated using TrypLE at 37°C for 4 minutes and the 
reaction was inhibited using complete cell media, centrifuged to remove debris and repeated 
twice. DRG cells were counted using a Bürker chamber and diluted in Neurobasal cell culture 
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media supplemented with 2% B27, 0.5 mM L-glutamine and penicillin/streptomycin. DRG 
cells were seeded in black 384-well view plates with clear bottom from Perkin Elmer. Assay 
plates pre-coated with poly-D-lysine (PDL) were coated with 0.01% fibronectin and dried in 
the hood just before plating of cells. 
PC12 cells from ATCC were cultured adherent in collagen IV coated flasks in DMEM medium 
supplemented with 10% FBS, 5% horse serum and penicillin‐streptomycin. Before assay, 
PC12 cells were diluted in DMEM medium supplemented with 1% horse serum and penicillin‐
streptomycin to support NGF dependent differentiation, and seeded in black 384-well view 
plates, pre-coated with PDL and coated with collagen IV. 
DRG neurons or PC12 cells were treated with various concentrations of NGF (27 kDa, 
PeproTech, Rocky Hill, NJ, USA), mutant NGF (Acturum, Södertälje, Sweden), or compound 
for 2-8 days, according to the protocol in each study. Cells were incubated at 37°C in a 
humidified atmosphere with 5% CO2 without any change of media until fixed in 4% (v/v) 
formaldehyde solution. Cells were permeabilized by incubation in 0.3% Triton X-100 in TBS 
and blocked with 2.5% BSA in 0.3% Triton X-100 in TBS to reduce non-specific binding for 
one hour at room temperature. Primary antibody incubations were performed in blocking 
solution overnight at 4ºC. Primary mouse anti-β-tubulin antibody was used to detect 
microtubules found along the neurites. Primary rabbit anti-phospho-p44/42 (pERK1/2) 
antibody was used to study activation of the ERK1/2 protein, a presumable TrkA or TrkB 
down-stream signaling event linked to cell proliferation, survival and differentiation, and 
functions in learning and memory (Peng et al., 2010; Zhou et al., 2014). 
Secondary antibody incubations were performed using goat anti-mouse Alexa-488 or goat anti-
rabbit Alexa-647, incubated together with Hoechst nuclear stain, in blocking solution. Cellular 
nuclei were quantified using Hoechst and cells were defined as β-tubulin positive objects with 
nucleus and cell soma, and neurite outgrowth was defined as average neurite length per valid 
cell in micrometer. Objective automated imaging analysis ensured unbiased quantification and 
results were exported as mean values per well. 
 
3.3.2.5 Hippocampal activation of ERK1/2 
Memory problems, learning difficulties and cognitive dysfunctions are shown to be associated 
with dysfunctional BDNF/TrkB signaling and hippocampal alterations, therefore the activation 
of the down-stream signaling protein ERK1/2 was analyzed in the mouse hippocampus after 
compound treatment.  
Male C57BL/6J mice received subcutaneous (s.c.) injections, 1 mg/kg/day of AC-25793 or 
PBS vehicle, for five consecutive days. 3 hours after the last injection, animals were 
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decapitated, and hippocampus was dissected. Quantification of phospho-ERK1/2 levels in the 
hippocampus were performed by western blot analysis. 
 
3.3.2.6 Long-term potentiation 
Hippocampal LTP is the cellular mechanism for memory formation induced by glutamate 
release which has been shown to be potentiated by BDNF (Abrahamsson et al., 2016; Woo and 
Lu, 2009). Electrophysiological LTP studies were performed as described earlier 
(Abrahamsson et al., 2016; Ho et al., 2011). Briefly, Sprague Dawley male rats were deeply 
anesthetized using isoflurane, brains were removed, and horizontal hippocampal sections were 
prepared to maintain the connections in the Shaffer collaterals (SC)/CA1 pathway (Fig. 9). 
After slicing at 34°C, slices were cooled down to room temperature and then allowed to recover 
for 2 hours. Slices were transferred to submerged recording chambers, perfused with in-house 
prepared artificial cerebrospinal fluid (aCSF) at 32°C and bubbled with carbogen gas (5% CO2, 
95% O2). Field excitatory postsynaptic potentials (fEPSPs) were recorded using standard 
electrophysiological equipment. Presynaptic stimulation was applied in the SC (CA3 region) 
and postsynaptic signals were recorded in stratum radiatum (CA1 region), both the stimulatory 
electrode and the recording pipette were placed extracellularly. 
After 30 minutes of baseline recordings, a subthreshold theta-burst (θ-burst) stimulation was 
delivered to the SC. The normalized fEPSP slope was calculated after recordings in the CA1 
region of control slices treated with aCSF which were compared with slices treated with BDNF 










To elucidate the biochemical effects of ACD855 on neurotransmitter release in the brain of 
rats, a microdialysis experiment was performed. A small microdialysis probe was placed in the 
ventral hippocampus and inserted using a guide cannula on an awake rat, see figure 10.  
 
A   B 
   
 
Figure 10. (A) The principle of the microdialysis procedure (König et al., 2018). (B) Schematic illustration of a 
microdialysis probe (Wikipedia). 
 
 
The probe was perfused at a constant flow-rate with aCSF solution and baseline levels of 
neurotransmitters were recorded for 4 hours, followed by perfusion with 30 µM ACD855 
dissolved in aCSF solution while collecting samples for another 4 hours. The microdialysis 
experiment was finalized with a wash-out period for 2 hours with aCSF solution and sampling. 
Animals were sacrificed by an overdose of isoflurane and neck dislocation. The brains were 
removed, frozen on dry ice and stored at -80°C for biomarker analysis or histological 
verification. 
 
3.3.3 Behavioral tests 
The rationale for testing the compounds in behavioral tests evolved from potent enhancing 
effects on the TrkA and the TrkB receptor in vitro in combination with a subset of down-stream 
signaling events, neurite outgrowth abilities, and hippocampal in vivo studies in rodents. 
 
3.3.3.1 Morris water maze 
The Morris water maze is a test for spatial learning, where the animal is placed in a large water 
tank (180 cm wide, 45 cm deep, filled to 28 cm with 23°C tap water) and seeks a hidden 
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platform (10 cm wide, 1 cm below water surface) with the help from distal ques (Kuteeva et 
al., 2005; Morris et al., 1982). The procedure is repeated several times and an animal with good 
cognitive abilities will find the hidden platform more rapidly after each trial, while an animal 
with dysfunctional cognitive abilities will continue to search for the platform without improved 








Compound (ACD855, 3 mg/kg) or vehicle (20% DMSO in 0.1 M sodium phosphate buffer 
pH 8.0) were injected s.c. for 10 consecutive days. Behavioral testing was performed day 5-10 
with additional injections of scopolamine (0.3 mg/kg) or vehicle (saline) during the days of 
behavioral training. Scopolamine causes a transient memory deficiency with a reduced ACh 
signaling due to blocking of muscarinic receptors (Bartus, 2000; Bymaster et al., 1993). The 
time to find the hidden plat form (swim latency), swim speed, probe trial (where plat form is 
removed) and time spent in target quadrant (where the hidden plats form was situated), were 
analyzed. The experiment was divided into two sessions to be able to perform the experiments 
at approximately the same time of the day for all animals. Each session included 16 animals 
and unpaired t-tests were used for groupwise comparisons to ensure non-significant differences 
between sessions. 
 
3.3.3.2 Step-through passive avoidance task 
The passive avoidance task is a test used to study memory and cognition in rodents. The passive 
avoidance model has been refined and optimized by our group (Madjid et al., 2005). The 
passive avoidance test is based on an aversive stimulus, such as the short and weak, but slightly 
painful foot-shock delivered through the stainless-steel bar floor in the dark and preferred area 
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of the test case. The test chamber is divided into a bright and a dark compartment, with an 
automatic door between the two chambers. Before the first trial, the animals were injected with 
test compound (AC-25793 or ACD855) or vehicle (PBS for AC-25793 or 20% DMSO in 0.1 M 
sodium phosphate buffer pH 8.0 for ACD855) for 4 consecutive days according to the protocol 
in each study. 30 minutes before the training session day 4, animals were also injected with a 
single dose of scopolamine (0.3 mg/kg) or MK-801 (0.3 mg/kg) to induce cognitive 
dysfunction in selected groups according to protocol in each study. MK-801 cause a memory 
deficiency due to NMDA receptor blocking. A single dose of the TrkB inhibitor ANA-12 
(0.5 mg/kg) was injected to study the BDNF/TrkB dependent effect of ACD855 in the passive 
avoidance model. A single low dose of 0.025 mg/kg physostigmine was injected to study the 
additive effect on a sub-effective dose of ACD855 (1 mg/kg). On the training day, the animal 
was placed in the bright compartment with the door closed and when the door was opened after 
1 minute, the animal searched for protection in the dark compartment, where it got a mild foot-
shock (0.35-0.4 mA, for 2 seconds, scrambled current). The time to enter the dark compartment 
on the training day is referred to as the training latency. 24 hours later (test day), the animal 
was reassembled to the bright compartment and when the door was opened, the time for the 
animal to enter the dark compartment was measured, referred to as the retention latency. 
Animals with normal learning and memory will avoid entering the dark chamber on the test 
day, where it received a foot-shock. 
To be able to perform the experiments at approximately the same time of the day for all animals, 
the experiment with AC-25793 was divided into two sessions. Unpaired t-tests were used for 
groupwise comparisons to analyze if the animals performed differently in session one and 
session two, which was not the case and therefore the two sessions were analyzed as one single 
experiment. 
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Figure 12. The passive avoidance paradigm. A.) Training in shuttle-box with a mild foot-shock day one. 




   
 
Table 3. Experimental design of the passive avoidance experiment presented in Study III-IV. 
 
 
3.3.3.3 Forced swim test 
In addition to its connection to synaptic plasticity and memory formation, BDNF has been 
shown to be associated with depression and mood disorders. Depression, depressive symptoms 
and use of antidepressants are common in AD (Chi et al., 2014; Enache et al., 2016). Following 
the cognitive evaluations with the neurotrophin enhancing compounds, the FST, a test for 
depression-like symptoms in mice or rats, was performed. The FST was developed by Porsolt 
(Porsolt et al., 1977) and the test used in this thesis was modified by Kuteeva et al (Kuteeva et 
al., 2005). 
The FST uses a cylinder, half filled with lukewarm water. The size of the container and the 
water level is chosen to avoid that the animal can climb out of the water filled container or 
touch the bottom. Injections of test compound (AC-25793 or ACD855) or vehicle (PBS for 
AC-25793 or 20% DMSO in 0.1 M sodium phosphate buffer pH 8.0 for ACD855) were given 
s.c. for five consecutive days and injections of reference compound (fluoxetine) or saline 
vehicle was given s.c. as a single administration 30 minutes before the FST day 5. A 10 minutes 
pre-swimming session was used to build up a stressor, which has been shown to evoke a 
depression-like behavior, and the test was performed for 6 minutes the following day. When 
the animal was placed in the cylinder, it immediately started intense swimming (Fig. 13A).  
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Figure 13. C57BL/6J mice in the forced swim test. (A) Intense swimming. (B) Immobile floating behavior. 
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AC-25793 or ACD855 injections X X X X
Physostigmine or ANA-12 injection X








On the test day, shortly after the animal was placed in the water tank, it gave up swimming and 
exhibited a distinctive immobility (Fig. 13B). The animals altered between swimming and 
floating during the 6 minutes task, with more and more floating towards the end of the test. The 
immobility time is considered an index of depression-like behavior and is defined as the time 
spent floating with maximum one paw moving to keep the balance. The swimming and 
immobility behaviors were monitored, and either video recorded or measured directly. 
 
   
 
Table 4. Experimental design of the forced swim test in Study III-IV. 
 
 
3.3.4 Statistical analysis  
The software GraphPad Prism (GraphPad Software, Inc., La Jolla, CA, USA), was used for all 
statistical calculations. Half maximal effective concentrations (EC50 values) and half maximal 
inhibitory concentration (IC50 values) was calculated using non-linear regression analysis. An 
unpaired t-test was used to compare two groups. To test whether dose-response curves differed 
from each other, non‐linear regression with extra sum‐of-squares F test was used. The overall 
treatment effects were analyzed using a one-way analysis of variance (one-way ANOVA) for 
all experiments with more than two groups, except for the Morris water maze, which was 
analyzed using a two-way ANOVA with repeated measurements. If significant, Bonferroni or 
Tukey’s multiple comparison tests were performed to assess statistical difference between 
groups. The level of significance was set at 0.05. 
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4 RESULTS AND DISCUSSION 
In this section, the main findings from the studies included in this thesis are summarized and 
discussed. More detailed results are found in each study. The main aim in this thesis was to 
advance drug discovery projects within non-amyloid pathways in AD and two non-
amyloidogenic approaches for treatment of AD have been studied. 
 
1. Inflammation, reactive oxygen species and 15-LO-1: Knowledge on the function of the 
15-LO-1 enzyme in relation to drug development in AD is limited. The development in 
Study I of a high-throughput screening assay and the indentification of potent 15-LO-1 
inhibitors enables the evaluation of small molecules affecting the 15-LO-1 enzyme activity 
in inflammatory diseases such as AD.  
 
2. Neurodegeneration, cognitive dysfunction and neurotrophins: The involvement of the 
neurotrophins in neurodegeneration, AD and memory impairment is well known but more 
detailed knowledge on different types of NGF and effects on NGF and BDNF signaling is 
needed. Study II evaluates NGF mutants and their ability to affect TrkA signaling and 
neurite outgrowth abilities. Study III and IV describe drug discovery and identification of 
two small molecules that potentiate the NGF/TrkA and the BDNF/TrkB signaling with 
positive effects in behavioral models of cognition and depression. 
 
4.1 STUDY I 
Development of a fluorescent intensity assay amenable for high-throughput screening for 
determining 15-lipoxygenase activity 
 
Arachidonic acid and its metabolites are key players in the immune response, with both pro- 
and anti-inflammatory actions. Elevated levels of 15-LO-1 is found in airway tissues of patients 
with asthma, in certain cancers and in affected brain regions in AD (Mattoli et al., 1990; Praticò 
et al., 2004).  
Several studies have shown the involvement of 15-LO in AD or AD-like animal models. 
Increased levels of 15-HETE has been shown in CSF and in frontal and temporal regions of 
the brain in AD patients (Praticò et al., 2004; Yao et al., 2005). Reduction of the animal 
ortholog 12/15-LO has shown improvement of memory deficits, reduced Aβ pathology and 
improved tau pathology in the AD-like transgenic mouse model (Chu et al., 2015; Joshi et al., 
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2015). But, the lack of potent and selective 15-lipoxygenase inhibitors has hampered the 
pharmacological validation of 15-LO-1.  
To identify inhibitors of 15-LO-1 a high-throughput screen was performed. This study started 
with assay development and small-scale screening of potential 15-LO-1 inhibitors. Early in the 
project the Hodgkin Reed-Sternberg L1236 cell line was identified as a suitable cell assay for 
the project with high endogenous levels of the 15-LO-1 protein (Claesson et al., 2008). An 
enzyme assay with purified human 15-LO-1 enzyme and a cell assay using the L1236 cells 
were developed and implemented in parallel. Chemical synthesis, SAR analysis and structure 
development were performed by the medicinal chemistry team members. 
Both the 15-LO-1 enzyme assay and the L1236 cell assay were examined using HPLC analysis. 
With higher demands on compound testing and approaching an HTS campaign, the need for a 
cheaper, faster and less labor-intensive analysis method was of great interest. Many HTS assays 
use absorbance or fluorescent signals to detect the production or the disappearance of a product 
or substrate in the assay, which is shown to be a stable and efficient analysis method. In this 
project, we developed for the first time a screening assay using the DPPP compound with a 
fluorescence analysis method. The lipid hydroperoxides, 15-HPETE or 13-HPODE, formed 
when 15-LO-1 catalyzes the peroxidation of arachidonic acid or linoleic acid were evaluated 
to directly oxidize the non-fluorescent DPPP compound in a one-step reaction by forming 
DPPP-oxide. By quantifying the fluorescence at 380 nm, we could indirectly measure the 
formation of the 15-LO-1 hydroperoxide metabolites. 
To optimize the assay, we decided to use the substrate with the highest 15-LO-1 catalytic 
efficiency, which was linoleic acid. The assay involved the addition of linoleic acid to the 
15-LO-1 enzyme mixture or the cell suspension to initiate the reaction. The reaction was 
stopped by the addition of methanol or methanol containing 0.125 mM DPPP. Analysis of 
formed 13-HPODE/13-HODE was performed using HPLC or fluorescence. 
Except for the transformation from HPLC analysis to fluorescence analysis, the assay was also 
transferred from a 96-well format to a 384-well format. This mainly cuts the cost, since the 
number of plates, amount of enzyme or cells, and chemicals can be reduced. In an HTS setting, 
automatization is important to reduce the labor intensity and to minimize human mistakes. The 
HTS assay developed in this study was automated using a Biomek NX robot. However, 
aspiration and dispensing of DPPP dissolved in pure methanol encountered difficulties with 
the surface tension using the 384-channel robotic head. To circumvent these problems, DPPP 
was dissolved in a mixture of methanol and DMSO (1:1 ratio). The background fluorescence 
increased using DMSO in the stop solution, which caused a slight decline in assay quality. Both 
signal-to-background (S/B) ration and Z-prime factor (Z’) values decreased with DMSO in the 
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solvent solution. Z’ factor was still above 0.4 in the fluorescent assay, which is set as a common 





Table 5. Summary of assay parameters from the 15-LO-1 HTS assay development (Dahlström et al., 2010). 
 
 
The quality of the assays were carefully monitored during assay development (Zhang et al., 














Z′ factor = 1 −
(3 x SD max + 3 x SD min)




S/B = Signal-to-background 
%CV = Coefficient of variation 
SD = Standard deviation 
max = max controls = absence of inhibitor 




The fluorescent assay for the quantification of 15-LO-1 activity was developed using the non-
fluorescent DPPP compound which is oxidized to the fluorescent DPPP-oxide by the 
hydroperoxide formed when 15-LO-1 catalyzes a polyunsaturated fatty acid. The formation of 
DPPP-oxide was found to be linear with the product formation of AA or LA metabolites within 
the defined concentration interval used. Since the reaction can be carried out at room 
temperature and the DPPP-oxide is stable for up to 2 hours, it is a convenient method and well 
suitable for HTS campaigns, where several plates can be analyzed consecutively.  
The assays were suitable for both enzyme and cell analyzes and could be transformed from a 
96-well format to a 384-well format. Using this assay, several potent 15-LO-1 inhibitors such 
as BLX-000769 (also known as BLX769) were identified. BLX769 has been further 
investigated by others. Recently, Archambault and colleagues showed that BLX769 is a 
potent 15-LO-1 inhibitor in human eosinophils, one of the key effectors of inflammatory 
responses (Archambault et al., 2018) giving further support to the 15-LO involvement in 
inflammation.  
There are of course limitations as in all studies. In Study I, a methodological limitation was that 
also 5-LO inhibitors were identified as positive inhibitors, which could be solved by a 5-LO 
selectivity assay. Another limitation was the aspiration and dispensing of DPPP dissolved in 
pure methanol using the 384-channel robotic head, which encountered difficulties with the 
surface tension. To circumvent these problems, DPPP was dissolved in a mixture of methanol 
and DMSO (1:1 ratio). The background fluorescence increased using DMSO in the stop 
solution, which caused a decline in assay quality. Eventually could this problem be solved by 
adding the stop solution using a multi-drop instead of a 384-channel robotic head. 
A possible limitation to this study would be that inhibition of the 15-LO-1 protein might be 
beneficial or disadvantageous at different stages of the disease progression. Another relevant 
question is if the inhibition of 15-LO-1 in AD provide a window-of-opportunity where 
treatment effects will be beneficial. Further studies are clearly needed on the effect of 15-LO-1 
on inflammation in AD.  
In summary, a human 15-LO-1 cell and enzyme assay amenable for HTS screening of small 
molecular compounds, with a new application of DPPP was developed. The assay is robust and 
accurately targets 15-LO-1 activity. The identified inhibitors of the 15-LO-1 can then be used 




4.2 STUDY II 
Identification of amino acid residues of nerve growth factor important for neurite outgrowth 
in human dorsal root ganglion neurons 
 
NGF signaling is found important for cell survival, differentiation and proliferation, and BFCN 
degeneration is linked to reduced NGF signaling via TrkA and AD pathology. A small 
molecular treatment designed to enhance NGF/TrkA signaling is a suggested target for the 
treatment of AD, while there is a risk to enhance pain signaling which was shown with 
intracerebroventricular infusion of NGF to three AD patients (Eriksdotter Jonhagen, 1998). 
This pain eliciting response with intracerebroventricular delivery may be caused by affecting 
the DRG and hypothalamus function (McKelvey et al., 2013).  Although, this pain signaling 
effect was not found when NGF was administered directly into the brain parenchyma in rats 
(Hao et al., 2000) or in individuals with AD (Eriksdotter-Jönhagen et al., 2012; Eyjolfsdottir et 
al., 2016; Tuszynski et al., 2005). 
To further investigate NGF/TrkA and its down-stream signaling, we performed a study with 
NGF mutants. Professor Cattaneo and colleagues have coined the phrase “painless” NGF with 
respect to the HSAN V mutant NGF-R100W and its potential as a neuroprotective treatment 
without the pain side-effects (Capsoni et al., 2017, 2012, 2011b; Cattaneo and Capsoni, 2019; 
Covaceuszach et al., 2010; Malerba et al., 2015). Both the Italian group and our group have 
studied a variant of the HSAN V mutant, NGF-R100E, with equivalent properties to the 
naturally occurring mutant, NGF-R100W (Capsoni et al., 2011b). In our study we also included 
two additional mutants, an NGF mutant related to the lipid binding site on NGF in mast cells, 
NGF-W99A (Tong et al., 2012) and a double mutant related to neurite outgrowth properties, 
NGF-K95A/Q96A. The mutated amino acids, 95, 96, 99 and 100, are in close proximity to 
each other and are depicted in figure 14. 
 
 
Figure 14. An X‐ray structure of the interacting part of the NGF-dimer in yellow and the extracellular D5 domain 
of the TrkA receptor in blue (Dahlström et al., 2019). 
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In Study II, the activation of the TrkA receptor at tyrosine 490 (the SHC1 binding site) and at 
tyrosine 785 (the PLC1 binding site) was examined in U2OS-TrkA/p75-SHC1 cells or U2OS-
TrkA-PLC1 cells using the PathHunter® assay described above, where we compared wild-
type NGF with the three NGF mutants, R100E, W99A and K95A/Q96A. In addition, cell 
survival, neurite outgrowth and ERK1/2 activation were studied in human DRG neurons and 
in PC12 cells. We found that NGF-W99A and NGF-K95A/Q96A displayed lower potency to 
induce TrkA and ERK1/2 signaling, and a decreased ability to induce cell survival and neurite 
outgrowth compared with wild-type NGF. These results indicate that amino acid 95, 96 and 99 




Figure 15. Analysis of human fetal cultured DRG neurons treated with NGF, mutant NGF or vehicle. Cultures 
were stained with Hoechst nuclear stain to label cell nuclei (blue), anti‐β‐tubulin antibody to label cell bodies and 
neurites (green) and anti‐phospho‐pERK1/2 (red). 
 
 
On the contrary, the NGF-R100E mutant displayed potent effects on TrkA signaling and the 
examined down-stream events. We showed that the R100E mutant was more potent than both 
wild-type NGF, W99A and K95A/Q96A regarding activation of TrkA at the SHC1- and the 
PLC1-site in recombinant cells, and cell survival, neurite outgrowth and ERK1/2 
phosphorylation in human DRG neurons (Fig. 15). The potent activation of NGF-R100E 
mutant at the TrkA-PLC1 phosphorylation site (Y785) in U2OS-TrkA/p75-SHC1 cells was 
somewhat surprising to us, since others had found reduced activation at this epitope of the 
NGF-R100E mutant compared to wild-type NGF in BALB/C 3T3 TrkA cells and in PC12 
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(Capsoni et al., 2011b). Albeit, we also found a reduced activity of NGF-R100E in PC12 cells 
at shorter incubation times (2-4 days), when studying cell survival and neurite outgrowth, and 
we could show that this effect was time dependent with increased potency after 6-8 days in 
culture. Our findings suggest that the choice of cell type and the incubation time may have 
substantial effects on the results. 
Our study demonstrates that the HSAN V-like NGF mutant NGF-R100E is a potent TrkA-
signaling enhancer, with superior cell survival and neurite outgrowth abilities compared with 
the wild-type NGF in human fetal DRG neurons. The NGF-R100E and the natural mutant 
NGF-R100W have been previously reported to have maintained binding affinity for the TrkA 
receptor and less binding affinity for the p75 receptor (Covaceuszach et al., 2010). It has also 
been shown in a homozygous NGFR100W/R100W mouse model the that number of cholinergic 
neurons are equally high in the basal forebrain and even increased in the striatum compared 
with wild-type mice (Testa et al., 2019a). 
The access to human fetal DRG neurons is a rate limiting step during assay development and 
in the number of experiments that can be performed, but we found it worth the effort to be able 
to study a human primary neuronal cell culture which is dependent on NGF for survival and 
differentiation. The ethical perspective of using human fetal tissue must be evaluated from 
study to study. Prior to an abortion, the woman is offered to donate fetal tissue for research, but 
she is under no pressure to donate and will receive equally good medical care whether she 
donates tissue or not. The use of human material is highly valuable for future treatments in 
neurodegenerative diseases. 
In summary, the combination with potent TrkA-signaling and subsequent neuronal protection 
and low pain signaling for the R100-mutants, offers a unique target for drug discovery of small 




4.3 STUDY III 
Steroid derivative AC-25793 enhances neurotrophin signaling and attenuates cognitive 
dysfunction in mice 
 
The cholinergic hypothesis suggests that short-term memory problems in AD are linked to 
decreased NGF signaling, which may cause degeneration of BFCN, and thus contributes to 
insufficient signaling of ACh (Craig et al., 2011). Long-term memory is formed and processed 
in the hippocampus. The cognitive dysfunctions and the long-term memory problems found in 
AD have been reported to be linked to hippocampal degeneration and BDNF deficiency 
(Miranda et al., 2019). 
To address the cognitive dysfunction associated with reduced neurotrophic support, we aimed 
to identify small molecules that could enhance TrkA and TrkB signaling to attenuate cognitive 
dysfunctions. A U2OS-TrkA cell-based assay was used, as described in section 3.3.2.1, and a 
high-through put screen of 25,000 compounds was performed. After validation of hits and 
additional screening of small focused libraries, a class of potent TrkA activators with a steroid 
backbone emerged. It has been shown before that steroid derivatives can improve cognition 
(Laudisio et al., 2009; Tohda et al., 2012) and we found the relationship with neurotrophin 
modulatory effects of interest and worth pursuing. 
Dose response curves for 88 steroid derivatives were evaluated using the U2OS-TrkA/p75-
SHC1 cell assay at 10 ng/ml NGF, thus studying TrkA phosphorylation at tyrosine 490 (Y490). 
Sixteen of these steroid derivatives displayed an enhanced signaling of TrkA with an EC50 
value below 500 nM. The most promising candidate for further evaluation, AC-25793, was 
selected based on its potent enhancement of TrkA and TrkB signaling and its good solubility 
in PBS. 
The structure of AC-25793 contains a cardenolide component and NMR studies revealed that 
AC-25793 and k-strophanthidin have all the stereocenters in the same configuration (Fig. 16).  
 
A  B 
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Figure 16. Chemical structure of the cardenolides (A) AC-25793 and (B) k-strophanthidin. The cardenolide 




With its quaternary nitrogen, AC-25793 is more water soluble than k-strophanthidin but less 
expected to pass the blood-brain barrier. The ester bond between the quaternary nitrogen and 
the cardenolide ring system is most likely susceptible to plasma hydrolysis and AC-25793 can 
thereby act as a soluble pro-drug to k-strophanthidin in vivo. 
In Study III we found that incubation of cells with AC-25793 led to increased phosphorylation 
of both the TrkA and the TrkB receptor, as assessed by potent enhancement of the signaling in 
U2OS-TrkA and U2OS-TrkB cells with EC50 values of 25 or 36 nM, respectively. AC-25793 
could activate down-stream events, demonstrated by the potentiation of NGF dependent neurite 
outgrowth in human fetal DRG neurons and potentiation of BDNF dependent ERK1/2 
phosphorylation in mouse primary cortical neurons. Also, injections of 1 mg/kg/day of 
AC-25793 for five consecutive days induced activation of ERK1/2 in the mouse hippocampus 
(without behavioral testing). Down-stream signaling of the Trk receptors may activate ERK1/2, 
which has been demonstrated to be critical for LTP, cell survival and cell differentiation (Lu 
and Xu, 2006; Marshall, 1995; Schafe et al., 2008). 
Based upon the potent effects on NGF- and BDNF-signaling in our examined models described 
above, we initiated behavioral studies with AC-25793. We started with s.c. injections of 3 or 
10 mg/kg in a few C57BL/6 male mice. Both these doses induced sedation and withdrawal a 
few minutes after compound injection and lasted for about 30 minutes, with less adverse effects 
in the lower dose tested. One hour after the injection, all mice displayed normal behavior again. 
Due to these transient adverse events at 3 and 10 mg/kg we decided to continue with a lower 
dose of 1 mg/kg, which did not cause any signs of discomfort such as sedation or withdrawal. 
Mice received s.c. injections once daily of either 1 mg/kg/day AC-25793 or PBS vehicle for 4 
consecutive days and a single dose of 0.3 mg/kg scopolamine or saline vehicle 30 minutes 
before the training session, which preceded the passive avoidance fear condition task. In 
scopolamine treated mice on the training day, neophobia was observed (Gutiérrez et al., 2003), 
which was shown by their caution to explore. To overcome this scopolamine induced 
neophobia, all mice were trained in the bright compartment for one minute the day before 
regular training, which solved all problems related to neophobia. Interestingly, treatment with 
AC-25793 was shown to attenuate the scopolamine induced cognitive impairment but 
displayed no enhanced effects on cognition, i.e. no pro-cognitive effects as defined by lack of 
an effect on non-scopolamine treated animals (Giessing and Thiel, 2012). 
Emerging evidence suggests that reduced BDNF/TrkB signaling is associated with depression 
(Castrén and Kojima, 2017; Levy et al., 2018; Malhi and Mann, 2018), therefore, after the 
cognitive test, we performed FST to assess the antidepressant effects of AC-25793 in mice. In 
 
56 
the FST, a training-swimming session of 10 minutes was performed the day before the test to 
build up a stressor. This learned helplessness or “behavioral despair” serves as a model for 
depression in rodents. Animals received s.c. injections once daily of either 1 mg/kg AC-25793 
or PBS vehicle for 5 consecutive days and/or a single dose of 20 mg/kg fluoxetine or saline 
vehicle 30 minutes before the 6 minutes FST, according to the protocol in each study. 
AC-25793 was shown to significantly improve the depression-like behavior (giving up 
swing/floating) in the FST, comparable to the effect by the antidepressant fluoxetine.  
Anti-depressant like effects have been shown in the rodent FST model by several compounds. 
Fluoxetine (Prozac), the first approved selective serotonin reuptake inhibitor (SSRI), which 
blocks the reuptake of serotonin into presynaptic neurons and prolong the effects of serotonin 
signaling on the 5-HT receptors, demonstrates anti-depressant effects in both humans and in 
rodents assessed by FST (Detke and Lucki, 1996; Perez-Caballero et al., 2014) and was used 
as a reference compound in the FST experiments in Study III and IV.  
An interesting observation regarding the studied class of steroid derivatives, is that AC-25793 
and k-strophanthidin belong to the class of cardenolides with inhibitory effects on the Na+/K+-
ATPase (the sodium-potassium pump). Indeed, all steroid derivatives with potent effects on 
TrkA and TrkB activation from this study (EC50 < 300 nM) were also potent Na
+/K+-ATPase 
inhibitors. The Na+/K+-ATPase is important for maintaining membrane potential in cells, with 
physiological implications in neuronal signaling, heart rate and recently in cognition. Two 
separate studies and a recent patent assigned cognitive improvement effects by Na+/K+-ATPase 
inhibitors (cardiac glycosides) in humans (Chen et al., 2016; Jang et al., 2010; Jeon et al., 2017; 
Kaphzan, 2019; Kilander et al., 1998; Laudisio et al., 2009; Papadopoulos and Lecanu, 2012; 
Tohda et al., 2012). 
One limitation observed in Study III is the narrow range where AC-25793 seems to have effect 
on cognition before adverse events appear, as demonstrated in the passive avoidance model in 
mice. A suggested treatment strategy would be a longer treatment period with low doses. 
The findings in Study III showed that AC-25793 enhanced TrkA and TrkB signaling and it is 
to our knowledge the first time that increased neurotrophin signaling is shown by an Na+/K+-
ATPase inhibitor. Future studies will explore whether the cognitive effect of these compounds 
is mediated via direct activation of Trk receptors, for example using a specific Na+/K+-ATPase 
inhibitor which by itself does not affect NGF/TrkA signaling. 
In summary, the in vitro and in vivo testing of steroid derivatives, and especially the cardenolide 
AC-25793, propose a group of potent enhancers of TrkA and TrkB signaling with significant 
effects on cognition and depression, worthwhile to study further. 
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4.4 STUDY IV 
The effects of ACD855 on neurotrophin signaling, cognition and depression 
 
During assay development, screening and validation of small molecular compounds in the HTS 
campaign performed in Study III, we identified a promising registered drug that could enhance 
signaling of TrkA and TrkB. With available safety and toxicology data, this compound was 
selected as the lead compound for further evaluations and was denoted ACD855. 
ACD855 could enhance TrkA or TrkB signaling in recombinant cells, in combination with 
10 ng/ml NGF or BDNF, with an EC50 of 1.9 or 3.2 µM, respectively. While ACD855 could 
only partially increase TrkA or TrkB signaling without neurotrophin present, this suggests that 
the substance is rather a positive modulator of neurotrophin signaling than a pure Trk agonist. 
ACD855 (20 µM) displayed significant potentiation of LTP in rat hippocampal slices after a 
single subthreshold theta-burst stimulation, comparable to exogenously added BDNF 
(50 ng/ml) as seen in figure 17. The effects by BDNF were expected since it is known that 
exogenously applied BDNF can induce LTP in hippocampal slices (Ikegaya et al., 2002; Ji et 




Figure 17. ACD855 elongates LTP induction in hippocampal rat slices comparable to exogenously added BDNF. 
Incubation with vehicle (aCSF), 50 ng/ml BDNF or 20 µM ACD855 generated an increased fEPSP slope which 
went back to normal levels after 35 minutes using vehicle, while both BDNF and ACD855 treatment induced an 
LTP (Study IV). 
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Microdialysis in the ventral hippocampus of Sprague Dawley rats was performed to study local 
in vivo effects of ACD855. Extracellular levels of neurotransmitters were analyzed in the 
microdialysis samples. Of the tested neurotransmitters (ACh, glutamate, dopamine, 
noradrenaline, and serotonin), ACh levels were significantly increased while the rest of the 
neurotransmitters were unaffected. 
The enhanced effect of ACD855 on both NGF and BDNF signaling is suggested to possess the 
potential to restore and improve both short-term and long-term memory problems observed in 
AD. The short-term memory problems seen in AD is associated with the early cholinergic 
neuronal degeneration and reduced ACh signaling, which is suggested to be linked to disturbed 
NGF/TrkA signaling. While the long-term memory formation is suggested to be mediated via 
BDNF/TrkB signaling in the hippocampal neurons, which are also highly vulnerable to the 
toxic environment in the AD brain. Treatment with ACD855 aiming for increased NGF/TrkA 
signaling may contribute to restoration of cholinergic neurons and improved short-term 
memory functions, while increased BDNF/TrkB signaling may contribute to improved long-
term memory processes, both at the receptor level and secondary to increased ACh signaling. 
ACD855 thus potentiates NGF/TrkA and BDNF/TrkB signaling in cultured cells, induces LTP 
in hippocampal slices from rats and increases ACh levels in vivo after local microdialysis 
administration in the rat hippocampus. 
In addition to cognitive effects by BDNF, exposure to stress and depression have shown to 
decrease BDNF expression in the hippocampus and the prefrontal cortex and conversely that 
antidepressant treatment can up-regulate BDNF in the adult brain (Duman et al., 2019). 
Therefore, to further characterize ACD855 we used a panel of behavioral models to study 
memory functions and depression. All behavioral tests were performed after daily s.c. 
injections for 4-5 consecutive days with ACD855 (1, 3 or 10 mg/kg). The cognitive tests, 
Morris water maze and passive avoidance, were performed using young healthy C57BL/6J 
mice with induced cognitive impairment using scopolamine or MK-801. The depression-like 
test, the FST, was performed in young healthy mice or in FSL rats, which display an 
endogenous depression-like behavior. 
In the Morris water maze, studying the swim latency parameter, ACD855 (3 mg/kg) treatment 
significantly attenuated the scopolamine induced cognitive impairment. Even a tendency for 
improved cognitive performance in cognitive normal mice was noted, shown by the 
significantly reduced swim latency in ACD855 treated mice day one compared with control 
mice. Next, the cognitive performance was studied using the passive avoidance fear 
conditioning test. Repeated administration of ACD855 (3 or 10 mg/kg) significantly attenuated 
both the scopolamine and the MK-801 induced cognitive impairment in the passive avoidance 
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task. Interestingly, the attenuated cognitive dysfunction by ACD855 was completely abolished 
when injected in combination with the TrkB antagonist, ANA-12, thus suggesting that the 
effect of ACD855 on cognition is TrkB dependent. Sub-effective doses of ACD855 
(1 mg/kg/day) and physostigmine (single dose of 0.025 mg/kg) improved cognitive functions 
in the passive avoidance test, suggesting that ACD855 treatment is additive to the AChEI 
physostigmine. No pro-cognitive effects of treatment with ACD855 using 3 or 10 mg/kg was 
noted in the passive avoidance task in non-scopolamine treated animals. 
Our findings that the TrkB antagonist ANA-12 eliminated the positive effects on cognitive 
function after ACD855 treatment in addition to the knowledge that BDNF also affects 
depression, made us curious to investigate whether ACD855 may have anti-depression-like 
effects. The depression-like effects of 3 mg/kg ACD855 (5 days treatment) was shown to be 
equally effective compared with a single dose of the SSRI fluoxetine (20 mg/kg) in mice, 
whereas in FSL rats, which have been shown to display a genetic suppression of ACh signaling 
(Overstreet, 1993), treatment with ACD855 displayed a significant anti-depressant effect while 
treatment with fluoxetine failed to reach significance. These results suggest that ACD855 can 
potentiate ACh signaling and counteract both cognitive problems and depression-like 
symptoms in rodents. 
The improved effects on both cognition and depression after repeated ACD855 treatment could 
have synergistic effects. Cognitive decline is found accelerated in individuals with depression 
(Rapp et al., 2011), and individuals with depression have increased risk to develop cognitive 
impairments (Enache et al., 2016). Thus, depression is suggested to both contribute to AD and 
be secondary to the disease (Hou et al., 2010), suggesting that a BDNF signaling enhancer such 
as ACD855, which both improves cognition and reduces depression, could possibly display 
greater improvements than the expected effect of treating one condition at a time. 
Previous studies have shown that NGF treatment caused low back pain and weight loss when 
administered intracerebroventricularly in the CNS (Eriksdotter Jonhagen, 1998) while 
administration directly into the brain parenchyma did not elicit pain in man (Eriksdotter-
Jönhagen et al., 2012; Tuszynski et al., 2005) or rodents (Hao et al., 2000). In the periphery, 
muscle pain was elicited after intradermal administration to healthy volunteers (Dyck et al., 
1997). The human mutations in HSAN IV (Congenital insensitivity to pain with anhidrosis, 
also known as CIPA) due to a null mutation in the TrkA gene (Indo et al., 1996) and the 
Swedish family with the HSAN V mutation in the NGF gene (Einarsdottir et al., 2004), both 
resulting in pain insensitivity, provided support for a link of NGF with pain mechanisms. This 
relation between NGF and peripheral pain has led to development of antibodies to NGF as pain 
therapeutics (Hefti, 2019). 
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Based on the above, systemic treatment with a neurotrophin signaling enhancing drug could 
potentially also show side effects such as pain and weight loss. When treating mice with 
ACD855 3-10 mg/kg/day for 4-5 days during behavioral studies, no signs of pain nor weight 
loss related adverse events were noted, while positive effects on cognitive dysfunction and 
depression-like symptoms were demonstrated. Moreover, long-term treatment of C57BL/6J 
young healthy mice with ACD855 3 mg/kg/day for 5 weeks did not show any weight-loss 
(Fig. 18) or other signs of pain or any other discomfort compared with control mice, indicating 




Figure 18. Injections with ACD855 3 mg/kg/day or with vehicle for 5 weeks to study weight gain/weight loss 
after compound treatment vs. vehicle. Data are presented as mean ± SEM (n = 16 animals per group). 
 
 
Limitations: Longer treatment periods than 5 weeks was not used, but in the literature and in 
our own experience from NGF treatment in AD patients and in rodents, side effects of pain 
developed quickly during treatment and delayed responses were not seen (Eriksdotter 
Jonhagen, 1998).  
 
In summary, this drug with the internal name ACD855, has been shown to display novel 
pharmacological effects on neurotrophin signaling, with subsequent ACh augmentation, 
attenuation of induced cognitive dysfunctions and anti-depressant effects.  
The interesting and encouraging data on the ACD855 presented in Study IV have led to pre-
clinical development of the compound, showing good safety and toxicology data after 28-days 
repeated dosing in rats and dogs, which provided the basis for a clinical phase 1 study in man. 
  




















5 CONCLUDING REMARKS AND FUTURE OUTLOOK 
 
For decades, much effort has been devoted to find a disease modifying treatment for AD. 
During the last ten years, knowledge about the disease progress and tools to diagnose the 
disease have evolved, but there is still no cure available.  
AD is a neurodegenerative disease characterized by Aβ plaques, neurofibrillary tangles and 
chronic inflammation in the brain. The main focus for drug discovery efforts has been to 
interfere with the amyloid pathway, which includes preventing production and aggregation, 
or increase the elimination of Aβ peptides. No anti-amyloid drug for the treatment of AD has 
yet reached the market. It is possible that AD is such a heterogeneous disease that a multi-
modal approach is necessary to stop the disease progress. 
The main aim of this thesis was to advance drug discovery projects within non-amyloid 
pathways in AD, by performing mechanistic studies, assay development and screening to 
identify small-molecule substances that can be used for further development of an AD 
treatment. 
 
From studies in this thesis we can show that: 
 
• A sensitive lipoxygenase assay to determine 15-LO-1 activity has been developed. 
DPPP was demonstrated to be a suitable substrate for detecting hydroperoxides using 
fluorescent analysis in HTS of small molecules targeting the 15-LO-1 protein. 
• Potent 15-LO-1 inhibitors, such as BLX-000769 have been identified and may be 
used further to study the inflammatory response in AD. 
• The NGF mutant NGF-R100E, which is a variant of the HSAN V mutant NGF-
R100W, displayed more potent effects on TrkA phosphorylation in recombinant 
TrkA-cells, and more potent effects on proliferation, differentiation and activation of 
ERK1/2 in human fetal DRG neurons compared with wild-type NGF. 
• Screening, validation and optimization of small-molecule compounds using the 
recombinant U2OS-TrkA or the U2OS-TrkB cell assays can identify compounds 
enhancing the NGF/TrkA or the BDNF/TrkB pathway, which translate well into 
effects on cognition and depression in rodents in vivo. 
• The cardenolide AC-25793 displayed potent stimulation of both the TrkA and the 
TrkB receptor, enhanced neurite outgrowth in human fetal DRG neurons, attenuated 
cognitive dysfunction and displayed anti-depressant like effects in mice. 
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• AC-25793 is a Na+/K+-ATPase inhibitor. For the first time, it was shown that a Na+/K+-
ATPase inhibitor increased neurotrophin signaling. 
• A registered compound, named ACD855 by us, displayed novel effects on TrkA and 
TrkB signaling with subsequent positive effects on cognition and depression in vivo. 
ACD855 was found to be safe and well tolerated. Based on these data, ACD855 was 
selected for further drug development and nominated a clinical candidate. ACD855 
is now in a clinical phase I study in man. 
 
This thesis contributes to the AD field with studies on drug targets for AD.  
 
1. Neurotrophin enhancers 
Studies in this thesis have contributed with drug discovery of two potent small-molecule 
compounds which enhance neurotrophin signaling, demonstrating data on both in vitro 
effects and in vivo behavioral improvements. Amazingly, this work has led to a potential 
clinical drug candidate for AD. ACD855 is now in phase I development.  
Both AC-25793 and ACD855 showed promising effects on cognition and depression. 
However, the potential of AC-25793 as an AD drug is limited due to its narrow range between 
an effect on cognition and adverse events, in contrast to ACD855 which displayed a much 
broader safety margin. The available cholinesterase inhibitors for the treatment of cognitive 
decline in AD are derived from the cholinergic hypothesis, in which the neurotrophin 
signaling plays a central role. Hence, a neurotrophin enhancer treatment has great potential 
to restore cholinergic neurons, enhance the neurotrophin signaling and thereby enhance the 
ACh signaling.  
Many anti-depressants found on the market are targeting the neurotransmitters serotonin, 
norepinephrine and dopamine, including the SSRIs. The effect of SSRIs is often delayed and 
it usually takes several weeks before the treatment effect is achieved, while the anesthetic 
compound ketamine displays rapid anti-depressant effects at low doses via inhibition of the 
NMDA receptor (Murrough, 2012). Unlike other anti-depressants, the effects of ketamine 
last significantly longer than the half-life of the compound. Emerging evidence suggest that 
the inhibition of excessive glutamate signaling via NDMA receptors by ketamine reduce the 
Ca2+ influx and increase BDNF expression, shown in mice, rats and humans, and may reflect 
BDNF triggered synaptic plasticity effects (Autry et al., 2012; Björkholm and Monteggia, 
2016; Garcia et al., 2008; Woelfer et al., 2019). The anti-depressant effect of our identified 
neurotrophin signaling enhancers, AC-25793 and ACD855, may induce BDNF derived 
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synaptic changes and anti-depressant effects without side effects related to ketamine or SSRI 
treatment. 
 
2. “Painless” NGF mutant 
Another approach worth further investigating as a potential therapy target for AD is the NGF 
mutant NGF-R100E, with its stimulatory effects on TrkA and its neurite outgrowth abilities, 
in addition to not affecting pain signaling. 
 
3. 15-LO-1 inhibitors 
The third contribution was the identification of 15-LO-1 inhibitors as potential future drug 
targets aiming at affecting inflammation in AD. The first step to identify 15-LO-1 inhibitors 
was to develop a sensitive lipoxygenase assay for HTS screening for 15-LO-1 activity, which 
has been achieved. Several 15-LO-1 inhibitors were tested as part of the development of the 
assay. One compound, BLX769, has been used by other researchers to detect 15-LO-1 
activity. 
Targeting the inflammation in AD is a struggle with both beneficial and harmful events. The 
15-LO-1 target is a puzzle with suggested pro- and anti-inflammatory arachidonic acid 
metabolites. At the same time, a target cannot be fully investigated until the hypothesis is 
tested. Now, there is a useful and sensitive assay available for determining 15-LO-1 activity 
which allows further development of the contribution of the 15-LO inhibitors to 
inflammatory treatment in AD. 
 
In conclusion, non-amyloid targets are highly interesting treatment strategies for AD.  Here, 
enhancers of both TrkA and TrkB signaling are shown to be particularly promising. Non-
amyloid treatments for AD might also be an adequate complement also if, or when, an 
amyloid-treatment is available. Since the disease is complex, multi-factorial and the timing 
of various treatment might be of great importance, a combination therapy targeting different 
mechanisms of AD may be the answer.   
To cure AD is the ultimate dream, but I believe that everything we can do to improve the 
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